Queensland Clinical Guidelines
Translating evidence into best clinical practice

Maternity and Neonatal Clinical Guideline

Early pregnancy loss
Document title: Early pregnancy loss
Publication date: May 2017
Document number: MN17.29-V5-R22
Document supplement: The document supplement is integral to and should be read in conjunction with this guideline
Amendments: Full version history is supplied in the document supplement
Amendment date: May 2018
Replaces document: MN17.29-V4-R22
Author: Queensland Clinical Guidelines
Audience: Health professionals in Queensland public and private maternity and neonatal services
Review date: May 2022
Endorsed by: Queensland Clinical Guidelines Steering Committee
Contact: Email: Guidelines@health.qld.gov.au
URL: www.health.qld.gov.au/qcg

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making in partnership with healthcare practitioners, including the right to decline intervention or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Health) 2018

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Australia. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en

For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au, phone (07) 3131 6777. For permissions beyond the scope of this licence, contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au, phone (07) 3234 1479.

Refer to online version, destroy printed copies after use
Flow Chart: Assessment of suspected early pregnancy loss

Clinical presentation
- Pregnancy < 20 weeks
- PV bleeding and/or
- Pain (abdominal, shoulder tip)

Haemodynamically stable?

Assessment
- History
- Confirm pregnancy
- Physical Exam
- Serial β-hCG
- USS (TVS preferred)
- FBC and blood group
- MSU as indicated
- STI screen as indicated

Ectopic pregnancy
Refer to flowchart: Ectopic pregnancy

Confirm pregnancy location

Intrauterine

Gestational Trophoblast Disease

Pregnancy viable?

Yes

Individualise pregnancy care

Stable non-viable IUP
Refer to flowchart: Stable intrauterine non-viable pregnancy

No

GTD
- Suction curettage
- Register with QTC
- Evaluate for persistent trophoblastic disease
- Serial β-hCG
- Recommend effective contraception
- Prolonged follow-up
- Early referral in next pregnancy

No

Resuscitation
- Initiate resuscitation
- Speculum exam
  ○ Remove any POC
- Urgent
  ○ β-hCG
  ○ Gynaecology review
  ○ USS
  ○ FBC, Group + Hold
- Consider surgical intervention

PUL
- Specialist review and follow-up essential
- Serial β-hCG
- Serial TVS

Refer to flowchart: Assessment of location and viability in suspected early pregnancy loss


Refer to online version, destroy printed copies after use
Queensland Clinical Guideline: Early pregnancy loss

Flowchart: Assessment of location and viability in suspected early pregnancy loss

Use clinical judgement and consider the woman’s individual circumstances when recommending management

Serum β-hCG → USS (TVS preferred) →

PUL

Specialist review
2x β-hCG
48–72 hours apart

Ectopic

Viable pregnancy

IUP

Fetal heart beat visible?

Yes

No

Suspicious for non-viable pregnancy

Serial β-hCG:
• rise of ≥ 66%
• fall of < 50%

Repeat TVS

MSD ≥ 25 mm

CRL ≥ 7 mm

Non-viable pregnancy

MSD ≥ 25 mm

CRL < 7 mm

Likely IUP (ectopic not excluded)

Likely non-viable (IUP or ectopic)
• Serial β-hCG
• Manage as indicated

TVS

If β-hCG
• < 2000 repeat in 1–2 weeks
• ≥ 2000 repeat within 1 week
Or when
• MSD estimated to be ≥ 25 mm

Fetal pole visible?

Yes

No

IUP observed?

Yes

No

Suspicious for non-viable pregnancy

Serial β-hCG
Repeat TVS in 7–10 days

Likely ectopic

Non-viable diagnostic criteria (TVS)

• MSD ≥ 25 mm and no fetus present
• Fetus with CRL ≥ 7 mm is visible, but no fetal heart movements demonstrated after observation of ≥ 30 seconds
• Absence of embryo with heartbeat ≥ 2 weeks after a scan that showed a gestational sac without a yolk sac
• Absence of embryo with heartbeat ≥ 11 days after a scan that showed a gestational sac with a yolk sac

TVS interval

• Estimate repeat TVS interval based on expected normal gestational sac growth rate of 1 mm/day

Worked example

• If MSD = 12 mm, repeat TVS in 13 days or more (12 mm MSD + 13 mm growth over 13 days equals expected MSD of 25 mm)

β-hCG: human chorionic gonadotrophin (all β-hCG measurements in International units/L (IU/L)), CRL: crown rump length, IUP: intrauterine pregnancy, MSD: mean sac diameter, PUL: pregnancy of unknown location, TVS: transvaginal scan, USS: ultrasound scan, ≥: greater than or equal to; ≤: less than or equal to

Queensland Clinical Guideline: Early pregnancy loss. Flowchart version: F17.29-4-V1-R22

Refer to online version, destroy printed copies after use
Flow Chart: Ectopic pregnancy

**Clinical presentation (may or may not include)**
- Absence of menses
- Irregular vaginal bleeding (spotting)
- Abdominal/shoulder tip pain
- Cervical motion tenderness
- Tachycardia and hypotension
- Palpable adnexal mass (50% of women)
- Absence of IUP on USS, with a positive β-hCG

Discuss care options relevant to woman’s preferences and clinical indications

**Medical**

**Indications**
- Haemodynamically stable
- No evidence of rupture
- No signs of active bleeding
- Normal FBC, ELFT

**Contraindications**
- Allergy to methotrexate
- Geographic isolation
- Potential non-compliance
- Presence of medical conditions (review on individual basis)
- Breastfeeding

**Caution**
- Baseline β-hCG > 5000 IU/L
- Ectopic > 3 cm on TVS
- Fetal heart motion present
- Blood transfusion not an option

**Methotrexate**
- If β-hCG ≤ 3000 IU/L, IMI
- If β-hCG > 3000 IU/L, IVI

**Ongoing management**
- EPAS or equivalent
- Serial β-hCG as per methotrexate protocol
- USS in one week then as clinically indicated
  - If fetal heart present, refer to MFM
- Avoid conception for 4 months due to potential teratogenicity

**Surgical**

**Indications**
- Haemodynamically unstable
- Signs of rupture
- Any β-hCG level
- Persistent excessive bleeding
- Heterotopic pregnancy
- Contraindications to medical or expectant management

**Procedure**
- Laparoscopy method of choice
- Laparotomy if:
  - Haemodynamically unstable
  - Laparoscopy too difficult

**Follow-up**
- GP 14 days post-surgery
- If salpingo(s)tomy, weekly β-hCG until negative
- If salpingectomy, urinary β-hCG 3 weeks after surgery
- USS if clinically indicated
- Optimal conception interval unknown (0–3 months common)

If medical or expectant:
- Risk of rupture in acute phase from sexual intercourse or pelvic exam
- Consider alternative management if indicated (e.g. β-hCG not falling, at woman’s request, tubal rupture or ongoing pain/bleeding)

Give written information about:
- Management option chosen
- Expected bleeding/symptoms
- Resumption of menstruation
- Contraception
- Follow-up arrangements

General care considerations
- Review histopathology of POC
- If indicated, recommend RhD-Ig
- Analgesia as required
- Communicate information to other care providers (e.g. GP)
- Early USS (5–6 weeks) in next pregnancy

Consider the woman’s psychological needs and offer access to support


Queensland Clinical Guideline: Early pregnancy loss. Flowchart version: F17.29-3-V5-R22
Flow Chart: Stable intrauterine non-viable pregnancy

### Expectant

**Indications**
- Woman’s preference
- Incomplete miscarriage

**Contraindications**
- Haemodynamic instability
- Suspected GTD
- Risk of haemorrhage or effects of haemorrhage
- Evidence of infection

**Requires**
- Access to telephone and 24 hour emergency care

**Ongoing management**
- Follow-up GP or EPAS 7–10 days
- Initial evaluation by history and examination
- Repeat β-hCG day 8
- Consider USS:
  - If clinically indicated
  - To assess for retained POC
  - If β-hCG not fallen > 90% over 7 days

**Give written information about:**
- Management option chosen
- Expected bleeding/symptoms
- Resumption of menstruation
- Contraception
- Follow-up arrangements

### Medical

**Indications**
- Woman’s preference
- Missed/incomplete miscarriage

**Contraindications**
- Haemodynamic instability
- Suspected GTD
- IUD (must be removed)
- Allergy to prostaglandins
- Evidence of infection
- Risk of haemorrhage or effects of haemorrhage
- Medical contraindications

**Misoprostol**
- Drug of choice
- Outpatient or day procedure

**Ongoing management**
- Follow-up EPAS days 2 and 8
- β-hCG day 1 and day 8
- Consider USS:
  - If clinically indicated
  - To assess for retained POC
  - If β-hCG not fallen > 90% over 7 days

**Give written information about:**
- Management option chosen
- Expected bleeding/symptoms
- Contraception
- Follow-up arrangements

### Surgical

**Indications**
- Woman’s preference
- Unsuccessful expectant or medical management

**Absolute indications**
- Haemodynamic instability
- Persistent excess bleeding
- Evidence of infected POC
- Suspected GTD

**Cautions**
- Risk of haemorrhage or effects of haemorrhage
- Previous uterine perforation

**Care provision**
- Misoprostol for cervical priming
- Routine antibiotics not required
- USS at time of suction curettage (if indicated)

**Follow-up**
- GP if ongoing concerns
- β-hCG not routinely indicated
- USS not routinely indicated

**General care considerations**
- Review POC histopathology
- If indicated, recommend RhD-Ig
- Analgesia as required
- Communicate information to other care providers (e.g. GP)

Consider the woman’s psychological needs and offer access to support

---


Queensland Clinical Guideline: Early pregnancy loss. Flowchart version: F17.29-1-V4-R22
Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-hCG</td>
<td>Beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>ELFT</td>
<td>Electrolytes, liver function test</td>
</tr>
<tr>
<td>EPAS</td>
<td>Early pregnancy assessment service</td>
</tr>
<tr>
<td>EPL</td>
<td>Early pregnancy loss</td>
</tr>
<tr>
<td>FBC</td>
<td>Full blood count</td>
</tr>
<tr>
<td>FMH</td>
<td>Fetomaternal haemorrhage</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>GTD</td>
<td>Gestational trophoblastic disease</td>
</tr>
<tr>
<td>HM</td>
<td>Hydatidiform mole</td>
</tr>
<tr>
<td>IUP</td>
<td>Intrauterine pregnancy</td>
</tr>
<tr>
<td>LNMP</td>
<td>Last normal menstrual period</td>
</tr>
<tr>
<td>MSD</td>
<td>Mean sac diameter</td>
</tr>
<tr>
<td>POC</td>
<td>Products of conception</td>
</tr>
<tr>
<td>PUL</td>
<td>Pregnancy of unknown location</td>
</tr>
<tr>
<td>PV</td>
<td>Per vaginam</td>
</tr>
<tr>
<td>QTC</td>
<td>Queensland Trophoblast Centre</td>
</tr>
<tr>
<td>RhD</td>
<td>RhD blood type</td>
</tr>
<tr>
<td>RhD-Ig</td>
<td>RhD immunoglobulin</td>
</tr>
<tr>
<td>TAS</td>
<td>Transabdominal ultrasound</td>
</tr>
<tr>
<td>TVS</td>
<td>Transvaginal ultrasound</td>
</tr>
<tr>
<td>USS</td>
<td>Ultrasound</td>
</tr>
</tbody>
</table>

Definition of terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anembryonic pregnancy</td>
<td>A type of early pregnancy failure where a gestational sac develops, but the embryo does not form.</td>
</tr>
<tr>
<td>Complete miscarriage</td>
<td>Complete expulsion of products of conception (POC). Further management of miscarriage by medical or surgical intervention is not required.</td>
</tr>
<tr>
<td>Early Pregnancy Assessment Service</td>
<td>A hospital-based service which is able to assess and manage early pregnancy loss. Equivalent services may have different names or structures across Queensland.</td>
</tr>
<tr>
<td>Early pregnancy loss</td>
<td>For the purposes of this document, early pregnancy loss refers to a loss within the first 20 completed weeks of pregnancy.</td>
</tr>
<tr>
<td>Ectopic pregnancy</td>
<td>Pregnancy located outside of the uterus, usually in the fallopian tubes but may be in the cornu, cervix, caesarean section scar, ovary, or in other sites.</td>
</tr>
<tr>
<td>Expectant management</td>
<td>No specific intervention; awaiting spontaneous passage of POC.</td>
</tr>
<tr>
<td>Gestational Trophoblastic Disease</td>
<td>A spectrum of disease characterised by an autonomous overgrowth of fetal chorionic tissue or trophoblast. Includes molar pregnancy (complete or partial).</td>
</tr>
<tr>
<td>Heterotopic pregnancy</td>
<td>Multiple pregnancy with an intrauterine plus ectopic pregnancy (e.g. tubal, cervical, ovarian, abdominal).</td>
</tr>
<tr>
<td>Incomplete miscarriage</td>
<td>Incomplete expulsion of POC.</td>
</tr>
<tr>
<td>Inevitable miscarriage</td>
<td>Miscarriage or expulsion of products is imminent or in the process of happening.</td>
</tr>
<tr>
<td>Medical management</td>
<td>Use of drugs to aid the expulsion of POC.</td>
</tr>
<tr>
<td>Miscarriage</td>
<td>Pregnancy loss occurring before 20 completed weeks of gestation or less than 400 g birth weight.</td>
</tr>
<tr>
<td>Missed miscarriage</td>
<td>Ultrasound confirmed non-viable pregnancy with no bleeding.</td>
</tr>
<tr>
<td>Pregnancy of unknown location</td>
<td>Refers to cases where a pregnancy test is positive but the pregnancy cannot be visualized by ultrasound.</td>
</tr>
<tr>
<td>Recurrent miscarriage</td>
<td>Three or more consecutive miscarriages. There is no specific term for non-consecutive pregnancy losses.</td>
</tr>
<tr>
<td>Threatened miscarriage</td>
<td>Any vaginal bleeding other than spotting before 20 weeks completed gestation with evidence of a progressive, viable pregnancy at ultrasound.</td>
</tr>
</tbody>
</table>
# Queensland Clinical Guideline: Early pregnancy loss

## Table of Contents

1. **Introduction** ................................................................. 9  
   1.1 Clinical standards .......................................................... 9  
   1.2 Principles of EPL care ..................................................... 10  

2. **Assessment** ................................................................. 11  
   2.1 Viability and location of pregnancy ................................. 12  
   2.2 Interpretation of β-hCG and TVS in a clinically stable woman .............................................. 13  
   2.3 Diagnosis of non-viable intrauterine pregnancy .......... 13  

3. **Haemodynamic instability** .............................................. 14  

4. **Ectopic pregnancy** .......................................................... 15  
   4.1 Risk factors for ectopic pregnancy ................................... 15  
   4.2 Expectant management of ectopic pregnancy ................... 16  
   4.3 Medical management of ectopic pregnancy ....................... 17  
   4.4 Surgical management of ectopic pregnancy ....................... 18  

5. **Non-viable intrauterine pregnancy** ................................. 18  
   5.1 Risk factors ................................................................. 18  
   5.2 Expectant management of non-viable intrauterine pregnancy .............................................. 19  
   5.3 Medical management of non-viable intrauterine pregnancy .............................................. 20  
   5.4 Surgical management of non-viable intrauterine pregnancy .............................................. 21  

6. **Second trimester pregnancy loss** ...................................... 22  
   6.1 Management of second trimester loss ................................ 23  

7. **RhD immunoglobulin** .................................................... 24  
   7.1 Administration of RhD immunoglobulin ......................... 25  
   7.2 Threatened miscarriage .................................................. 25  

8. **Gestational trophoblastic disease** ...................................... 26  

9. **Psychological support** .................................................... 27  
   9.1 Context and experience of early pregnancy loss .................. 27  
   9.2 Communicating with parents .......................................... 28  
   9.3 Supportive care ............................................................ 29  
   9.4 Creating memories ........................................................ 29  
   9.5 Psychological morbidity .................................................. 30  

10. **Recurrent early pregnancy loss** ....................................... 31  

11. **Sensitive management of fetal tissue/remain** .................... 32  

References ............................................................................. 33  

Appendix A: Early pregnancy assessment service ....................... 36  
Appendix B: Sonographic anatomy, landmarks and documentation .............................................. 37  
Appendix C: Methotrexate regimens for ectopic pregnancy .............................................. 38  

Acknowledgements ................................................................ 39  

## List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Clinical standards</td>
<td>9</td>
</tr>
<tr>
<td>1.2</td>
<td>Principles of EPL care</td>
<td>10</td>
</tr>
<tr>
<td>2.1</td>
<td>Viability and location of pregnancy</td>
<td>12</td>
</tr>
<tr>
<td>2.2</td>
<td>Interpretation of β-hCG and TVS in a clinically stable woman</td>
<td>13</td>
</tr>
<tr>
<td>2.3</td>
<td>Diagnosis of non-viable intrauterine pregnancy</td>
<td>13</td>
</tr>
<tr>
<td>3.1</td>
<td>Haemodynamic instability</td>
<td>14</td>
</tr>
<tr>
<td>4.1</td>
<td>Risk factors for ectopic pregnancy</td>
<td>15</td>
</tr>
<tr>
<td>4.2</td>
<td>Expectant management of ectopic pregnancy</td>
<td>16</td>
</tr>
<tr>
<td>4.3</td>
<td>Medical management of ectopic pregnancy</td>
<td>17</td>
</tr>
<tr>
<td>4.4</td>
<td>Surgical management of ectopic pregnancy</td>
<td>18</td>
</tr>
<tr>
<td>5.1</td>
<td>Risk factors</td>
<td>18</td>
</tr>
<tr>
<td>5.2</td>
<td>Expectant management of non-viable intrauterine pregnancy</td>
<td>19</td>
</tr>
<tr>
<td>5.3</td>
<td>Medical management of non-viable intrauterine pregnancy</td>
<td>20</td>
</tr>
<tr>
<td>5.4</td>
<td>Surgical management of non-viable intrauterine pregnancy</td>
<td>21</td>
</tr>
<tr>
<td>6.1</td>
<td>Management of second trimester loss</td>
<td>23</td>
</tr>
<tr>
<td>7.1</td>
<td>Administration of RhD immunoglobulin</td>
<td>25</td>
</tr>
<tr>
<td>7.2</td>
<td>Threatened miscarriage</td>
<td>25</td>
</tr>
<tr>
<td>8.1</td>
<td>Gestational trophoblastic disease</td>
<td>26</td>
</tr>
<tr>
<td>9.1</td>
<td>Context and experience of early pregnancy loss</td>
<td>27</td>
</tr>
<tr>
<td>9.2</td>
<td>Communicating with parents</td>
<td>28</td>
</tr>
<tr>
<td>9.3</td>
<td>Supportive care</td>
<td>29</td>
</tr>
<tr>
<td>9.4</td>
<td>Creating memories</td>
<td>29</td>
</tr>
<tr>
<td>9.5</td>
<td>Psychological morbidity</td>
<td>30</td>
</tr>
<tr>
<td>10.1</td>
<td>Recurrent early pregnancy loss</td>
<td>31</td>
</tr>
<tr>
<td>11.1</td>
<td>Sensitive management of fetal tissue/remain</td>
<td>32</td>
</tr>
<tr>
<td>12.1</td>
<td>Management of second trimester loss</td>
<td>23</td>
</tr>
<tr>
<td>13.1</td>
<td>Risk factors for ectopic pregnancy</td>
<td>15</td>
</tr>
<tr>
<td>14.1</td>
<td>Expectant management for stable non-viable IUP</td>
<td>19</td>
</tr>
<tr>
<td>15.1</td>
<td>Indications for medical management for the stable non-viable IUP</td>
<td>20</td>
</tr>
<tr>
<td>16.1</td>
<td>Surgical management of the stable non-viable IUP</td>
<td>21</td>
</tr>
<tr>
<td>17.1</td>
<td>Second trimester loss</td>
<td>22</td>
</tr>
<tr>
<td>18.1</td>
<td>Management options</td>
<td>23</td>
</tr>
<tr>
<td>19.1</td>
<td>Assessment for RhD immunoglobulin</td>
<td>24</td>
</tr>
<tr>
<td>20.1</td>
<td>Administration of RhD immunoglobulin</td>
<td>25</td>
</tr>
<tr>
<td>21.1</td>
<td>Threatened miscarriage</td>
<td>25</td>
</tr>
<tr>
<td>22.1</td>
<td>Gestational Trophoblastic Disease</td>
<td>26</td>
</tr>
<tr>
<td>23.1</td>
<td>Context and experience of early pregnancy loss</td>
<td>27</td>
</tr>
<tr>
<td>24.1</td>
<td>Psychological support considerations</td>
<td>28</td>
</tr>
<tr>
<td>25.1</td>
<td>Supportive care</td>
<td>29</td>
</tr>
<tr>
<td>26.1</td>
<td>Memory creation</td>
<td>29</td>
</tr>
<tr>
<td>27.1</td>
<td>Psychological morbidity</td>
<td>30</td>
</tr>
<tr>
<td>28.1</td>
<td>Recurrent early pregnancy loss</td>
<td>31</td>
</tr>
<tr>
<td>29.1</td>
<td>Sensitive disposal of fetal remains</td>
<td>32</td>
</tr>
</tbody>
</table>
1 Introduction

Early pregnancy loss (EPL) is a relatively common event, occurring in approximately 20% of pregnancies. Amongst women who have been pregnant, it is estimated that 25% will experience an EPL by the time they reach 39 years of age. EPL can have negative consequences physically and psychologically. Potential physical complications include infection, haemorrhage, embolism, damage to uterus and associated structures, and anaesthetic complications. Psychological complications such as grief, depression and anxiety are common.

Whilst health care professionals and clinical care can do little to prevent a threatened pregnancy loss from progressing, high quality care can increase levels of satisfaction with care, minimise negative outcomes, and support women and their families to navigate their way through an emotional and highly stressful time.

1.1 Clinical standards

Table 1. Clinical standards

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triage</td>
<td>• Triage women presenting with symptoms of EPL according to the Australasian Triage Score (ATS)</td>
</tr>
<tr>
<td></td>
<td>o Ideally within the first 20 minutes noting that this is a very stressful and emotional time for the woman and her family</td>
</tr>
<tr>
<td></td>
<td>• Assessment by an experienced clinician is required</td>
</tr>
<tr>
<td></td>
<td>• If haemodynamic instability, refer to Section 3 Haemodynamic instability</td>
</tr>
<tr>
<td>Care providers</td>
<td>• Women with suspected EPL may seek care through a variety of pathways and access points</td>
</tr>
<tr>
<td></td>
<td>• A dedicated outpatient early pregnancy assessment service (EPAS) is recommended for all maternity services</td>
</tr>
<tr>
<td></td>
<td>o Refer to Definition of terms and Appendix A: Early pregnancy assessment service</td>
</tr>
<tr>
<td></td>
<td>• Refer or transfer women to the most appropriate service provider (e.g. higher level service, gynaecologist, obstetrician, general practitioner (GP) or EPAS</td>
</tr>
<tr>
<td>Communication between care providers</td>
<td>• Inclusive and timely communication between care providers (internal and external to a healthcare facility) will optimise the woman’s experience of care</td>
</tr>
<tr>
<td></td>
<td>• Develop local protocols and pathways to facilitate communication about the woman’s care:</td>
</tr>
<tr>
<td></td>
<td>o Between emergency, outpatient, and maternity departments (e.g. so future maternity bookings and reminders can be cancelled)</td>
</tr>
<tr>
<td></td>
<td>• Provide timely written information to the woman’s GP</td>
</tr>
<tr>
<td>Staff support</td>
<td>• Support staff caring for women with EPL to access education about grief and loss, counselling and recognition and assessment of psychological morbidity</td>
</tr>
<tr>
<td></td>
<td>• Offer staff access to emotional support and debriefing as a routine part of service provision</td>
</tr>
<tr>
<td>Women’s choice</td>
<td>• Women’s treatment preference is a primary consideration when deciding management options</td>
</tr>
<tr>
<td></td>
<td>• Women are more motivated to follow their chosen treatment to completion when they have chosen it for themselves</td>
</tr>
<tr>
<td></td>
<td>• Provide an opportunity for women to:</td>
</tr>
<tr>
<td></td>
<td>o Make an informed choice regarding treatment options</td>
</tr>
<tr>
<td></td>
<td>o Consider their choices</td>
</tr>
<tr>
<td></td>
<td>• Delay decision making when safe to do so</td>
</tr>
<tr>
<td>Psycho-social support</td>
<td>• Provide care appropriate to the gestation and circumstances of each woman (including whether or not the pregnancy was wanted or planned)</td>
</tr>
<tr>
<td></td>
<td>• Consider the impact of cultural/spiritual beliefs and preferences when offering care to the woman and her family (e.g. taking photos, creating memories)</td>
</tr>
<tr>
<td></td>
<td>• Refer to Section 9 Psychological support</td>
</tr>
</tbody>
</table>
### 1.2 Principles of EPL care

Aspects of care common to all women experiencing EPL (regardless of pregnancy location or management option) are outlined in Table 2. Consider in conjunction with all care recommendations.

Table 2. General care principles for EPL

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Histopathology** | • Send products of conception (POC) obtained at the time of EPL or via surgical intervention for histopathology to confirm pregnancy and exclude ectopic pregnancy or unsuspected gestational trophoblastic disease (GTD)  
  o Transvaginal ultrasound (TVS) is not reliable in the detection of GTD  
  • Discuss implications/requirements for histopathology with women who may miscarry at home according to their individual circumstances  
  o May be practically difficult and some may find it distressing  
  o If POC collection chosen, provide a labelled specimen container, pathology request form and instructions for delivery to pathology  
  • If POC not collected, reassure that there are other options for follow-up |
| **Return to normal menstrual cycle** | • Resumption of normal menstrual cycle indicates resolution of EPL complications and completion of management⁸  
  • Ongoing, irregular bleeding requires follow-up—consider:  
  o Beta human chorionic gonadotrophin (β-hCG) to exclude GTD  
  o Retained products or infection⁹ |
| **Ongoing and follow-up care** | • There is limited evidence or consensus about optimal follow-up protocols  
  • Establish local procedures and protocols:  
  o For follow-up care arrangements  
  o To ensure histopathology results are reviewed and actioned as required  
  • Vary the recommendations for follow-up in this guideline as is clinically appropriate and indicated for individual women  
  • If GTD, register with Queensland Trophoblast Centre (QTC)  
  o Refer to Section 8 Gestational trophoblastic disease |
| **Advice to women after EPL** | • Provide information (written and verbal) to all women with EPL about:  
  o When to seek emergency assistance  
  ▪ If experiencing strong pain unrelieved by paracetamol  
  ▪ Shoulder tip or diaphragmatic pain  
  ▪ Soaking of more than one pad within 60 minutes  
  ▪ Fainting  
  ▪ Elevated temperature  
  o Timing and nature of follow-up investigations and appointments, including contact details of relevant care providers  
  o Resumption of sexual activity  
  o Contraception  
  o Recommendations for conception interval (if any)  
  o Future pregnancy planning  
  o Resumption of menstruation/expected bleeding  
  o Accessing psychological support  
  • Refer to Queensland Clinical Guidelines patient information:  
  o Ectopic pregnancy¹⁰  
  o Bleeding and pain in early pregnancy¹¹  
  o RhD negative in pregnancy¹² |
2 Assessment
Assessment and diagnosis is made through a combination of a physical examination, history, and clinical investigations. Initial assessment of haemodynamic stability is essential.

Table 3. Confirmation of pregnancy and assessment

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>History</td>
<td>• Menstrual history and last normal menstrual period (LNMP)</td>
</tr>
<tr>
<td></td>
<td>• Date of positive pregnancy test</td>
</tr>
<tr>
<td></td>
<td>• Previous pregnancies and outcomes, particularly miscarriages</td>
</tr>
<tr>
<td></td>
<td>• Other significant gynaecological history</td>
</tr>
<tr>
<td></td>
<td>• If assisted conception, identify method of conception</td>
</tr>
<tr>
<td></td>
<td>• Relevant ultrasound scan (USS) and quantitative β-hCG</td>
</tr>
<tr>
<td></td>
<td>• Symptoms of early pregnancy</td>
</tr>
<tr>
<td></td>
<td>• Presence of associated symptoms:</td>
</tr>
<tr>
<td></td>
<td>o Vaginal bleeding (timing, extent and severity)</td>
</tr>
<tr>
<td></td>
<td>o Pain (lower abdominal cramping or backache)</td>
</tr>
<tr>
<td></td>
<td>o Postural syncope</td>
</tr>
<tr>
<td></td>
<td>o Vomiting</td>
</tr>
<tr>
<td></td>
<td>o Shoulder tip/diaphragmatic pain</td>
</tr>
<tr>
<td></td>
<td>• Passage of POC</td>
</tr>
<tr>
<td>Confirm pregnancy</td>
<td>• Perform an urgent serum quantitative β-hCG (pregnancy test) on all</td>
</tr>
<tr>
<td></td>
<td>women of reproductive age presenting with a history of recent or current</td>
</tr>
<tr>
<td></td>
<td>abdominal pain, pelvic pain, shoulder tip pain and/or per vaginam (PV)</td>
</tr>
<tr>
<td></td>
<td>bleeding, syncope or signs of shock (irrespective of LNMP, contraception,</td>
</tr>
<tr>
<td></td>
<td>history of sterilisation or reported sexual inactivity)</td>
</tr>
<tr>
<td></td>
<td>o If delay in reporting a serum test is expected, use urine β-hCG as</td>
</tr>
<tr>
<td></td>
<td>clinically indicated</td>
</tr>
<tr>
<td></td>
<td>• A negative serum β-hCG essentially excludes ectopic (except in the</td>
</tr>
<tr>
<td></td>
<td>unusual circumstance of a chronic ectopic where β-hCG has been positive</td>
</tr>
<tr>
<td></td>
<td>in the recent past</td>
</tr>
<tr>
<td>Physical exam</td>
<td>• Baseline observations (temperature, heart rate, respiratory rate, blood</td>
</tr>
<tr>
<td></td>
<td>pressure)</td>
</tr>
<tr>
<td></td>
<td>• Abdominal examination</td>
</tr>
<tr>
<td></td>
<td>o Tenderness (rigidity and guarding)</td>
</tr>
<tr>
<td></td>
<td>o Distension</td>
</tr>
<tr>
<td></td>
<td>• PV blood loss (check loss on pad)</td>
</tr>
<tr>
<td></td>
<td>• Vaginal examination (individualised as clinically indicated):</td>
</tr>
<tr>
<td></td>
<td>o Speculum examination:</td>
</tr>
<tr>
<td></td>
<td>• Source and amount of bleeding</td>
</tr>
<tr>
<td></td>
<td>• Evidence of POC in the cervical os (if present, remove and submit for</td>
</tr>
<tr>
<td></td>
<td>• histology)</td>
</tr>
<tr>
<td></td>
<td>o Bi-manual examination:</td>
</tr>
<tr>
<td></td>
<td>• Cervical motion tenderness</td>
</tr>
<tr>
<td></td>
<td>• State of internal cervical os</td>
</tr>
<tr>
<td></td>
<td>• Assess for adnexal masses (ectopic pregnancy or other masses)</td>
</tr>
<tr>
<td></td>
<td>• Size of uterus relative to menstrual dates</td>
</tr>
<tr>
<td>Ultrasound scan</td>
<td>• Perform an USS as soon as possible and urgently if clinically indicated</td>
</tr>
<tr>
<td></td>
<td>• Document whether TVS or transabdominal (TAS) on the USS report to aid</td>
</tr>
<tr>
<td></td>
<td>interpretation</td>
</tr>
<tr>
<td></td>
<td>• Refer to Appendix B: Sonographic anatomy, landmarks and documentation</td>
</tr>
<tr>
<td>Other investigations</td>
<td>• Full blood count (FBC), blood group, antibody screen</td>
</tr>
<tr>
<td></td>
<td>• Midstream specimen of urine for microscopy, culture and sensitivity as</td>
</tr>
<tr>
<td></td>
<td>clinically indicated</td>
</tr>
<tr>
<td></td>
<td>• Screen for sexually transmitted infections as clinically indicated (e.g.</td>
</tr>
<tr>
<td></td>
<td>for women in high risk groups, relevant history)</td>
</tr>
</tbody>
</table>
## 2.1 Viability and location of pregnancy

### Table 4. Determining viability and location of pregnancy

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Ultrasound scan** | • TVS by an experienced sonographer is the gold standard in the first trimester  
• If TVS unavailable, TAS may be used, recognising that it is not as accurate as TVS for diagnosis of early pregnancy complications |
| **β-hCG** | • Serum β-hCG first becomes positive at 9 days post conception  
  o β-hCG greater than 5 IU/L confirms pregnancy  
  o A single β-hCG value does not differentiate between a viable and nonviable pregnancy\(^1\)  
  o For a potentially viable intrauterine pregnancy (IUP) up to 6–7 weeks gestation  
    o Mean doubling time for β-hCG is 1.4–2.1 days  
    o 85% show serial β-hCG rise of at least 66% every 48 hours\(^1\)  
    o 15% show serial β-hCG rise between 53–66% every 48 hours\(^1\)  
    o The slowest recorded rise over 48 hours is 53%\(^1\) |
| **Correlating β-hCG and TVS** | • USS and serial β-hCG enable the location and potential viability of an early pregnancy to be ascertained  
• Quantitative serum β-hCG levels used in conjunction with serial TVS are often the only way to distinguish between an early non-viable pregnancy and ectopic pregnancy in gestations less than 6–7 weeks |
| **Discriminatory zone** | • The discriminatory zone is the serum β-hCG level above which a gestational sac should be visible on TVS or TAS if an IUP is present\(^1\)  
• An IUP is usually visible on TVS when mean sac diameter (MSD) is greater than or equal to 3 mm, however one single β-hCG value may not be discriminatory and serial β-hCG is advised in stable circumstances  
• One study reported, where no IUP and no abnormal TVS findings and\(^1\):  
  o β-hCG 2000–3000 IU/L a 2% chance of subsequent viable IUP  
  o β-hCG greater than 3000 IU/L a 0.5% chance of subsequent viable IUP  
• Cautions:  
  o No proven discriminatory zone for β-hCG for multiple gestations  
  o In the presence of fibroids, USS may be less reliable |
| **Complete miscarriage** | • IUP can only be confirmed conclusively after identification of a yolk sac\(^1\)  
• If no prior report or evidence of an IUP, a diagnosis of complete miscarriage cannot be made based on TVS findings of an ‘empty uterus’  
• A diagnosis of complete miscarriage requires follow-up with serum quantitative β-hCG until negative and TVS if clinically indicated, to exclude undiagnosed ectopic |
| **Pregnancy of unknown location (PUL)** | • It may not be possible to confirm if a pregnancy is intrauterine or extra-uterine at first visit  
  o Specialist review and close follow-up is essential  
  o Serial β-hCG and TVS may be required |
| **Serum progesterone** | • If PUL, a single progesterone level may assist in identifying women with a low risk of having an ectopic pregnancy or persistent PUL\(^7\)  
  o In one study\(^7\) an initial serum progesterone of less than or equal to 2 nanomol/L correctly classified:  
    o 206 of 210 PUL as low risk for ectopic (negative predictive value 98%)  
    o 134 of 138 ectopic pregnancies as not low risk for ectopic (sensitivity 97%) |
2.2 Interpretation of β-hCG and TVS in a clinically stable woman

Table 5. β-hCG and TVS correlation in a clinically stable woman

<table>
<thead>
<tr>
<th>β-hCG</th>
<th>TVS</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| Greater than 2000 IU/L | No IUP, complex adnexal mass and/or free fluid | • High probability of ectopic pregnancy  
• Refer to Section 4 |
|                        | No IUP, no abnormal findings     | • Consider serum progesterone level  
• Repeat β-hCG from 48–72 hours  
• Repeat TVS as clinically indicated |
| β-hCG levels less than 2000 IU/L |                         | • Repeat β-hCG from 48–72 hours  
• If β-hCG rising over one week, then TVS (or earlier if clinically indicated) |
| β-hCG levels declining or sub-optimally rising |                         | • No IUP on TVS, indicates a non-viable pregnancy (intrauterine or ectopic)  
• Follow-up to ensure adequate resolution of either diagnosis |

2.3 Diagnosis of non-viable intrauterine pregnancy

Table 6. Diagnosis of non-viable IUP

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Context                         | • Previously accepted criteria for excluding a viable pregnancy has been shown not to be stringent enough to avoid interventions that inadvertently damage pregnancies that might have had normal outcomes<sup>16</sup>  
• Diagnosis of non-viable IUP requires:  
  o Experienced clinicians  
  o High quality TVS equipment and experienced operator<sup>16</sup> |
| Findings suspicious but not diagnostic<sup>16</sup> | • MSD 16–24 mm and no embryo  
• Crown rump length (CRL) less than 7 mm and no heartbeat  
• Absence of embryo with heartbeat 7–13 days after USS that showed a gestational sac without a yolk sac  
• Absence of embryo with heartbeat, 7–10 days after USS that showed a gestational sac with a yolk sac  
• Absence of embryo 6 weeks or more after LNMP  
• Empty amnion (amnion seen adjacent to yolk sac with no visible embryo)  
• Enlarged yolk sac (greater than 7 mm)  
• Small gestational sac in relation to the size of the embryo (less than 5 mm difference between MSD and CRL) |
| TVS diagnostic criteria<sup>18</sup> | • MSD is greater than or equal to 25 mm and no fetus present  
• Fetus with CRL greater than or equal to 7 mm is visible, but no fetal heart movements demonstrated after observation of at least 30 seconds  
• Absence of embryo with heartbeat 2 weeks or more after USS that showed a gestational sac without a yolk sac  
• Absence of embryo with heartbeat 11 days or more after USS that showed a gestational sac with a yolk sac |
| Repeat TVS interval             | • Diagnosis cannot be made until the MSD is (or has failed to reach) 25 mm therefore the interval between initial and subsequent USS is dependent on the MSD at initial presentation  
• Estimate TVS interval based on expected normal gestational sac growth rate of 1 mm/day  
  o Example: If MSD = 12 mm, repeat TVS in 13 days or more (12 mm MSD+13 mm growth over 13 days = expected MSD of 25 mm)  
• Avoids repeated inconclusive TVS |
3 Haemodynamic instability

Haemodynamically unstable women, presenting with vaginal bleeding and or pain (abdominal, diaphragmatic or shoulder tip pain) and who are believed to be pregnant, require urgent intervention. Presume ruptured ectopic pregnancy or incomplete miscarriage with cervical shock or massive haemorrhage.

Table 7. Haemodynamically unstable

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Resuscitate               | • Resuscitate as required following standard medical emergency procedures  
• Ensure sufficient IV access (e.g. two x 16 gauge IV cannulae)  
• Perform urgent speculum examination and remove POC from cervix and or vagina—this may stop vaginal bleeding and restore blood pressure  
• Insert indwelling catheter to empty bladder  
• Obtain urgent gynaecological review and USS concurrently with resuscitation  
• If ectopic pregnancy confirmed or unable to be excluded, continue resuscitation en route to theatre  
• Urgent FBC and group and hold |
| Control bleeding          | • If vaginal bleeding persists and ectopic has been excluded, consider pharmacological therapy  
• Refer to Queensland Clinical Guideline: Postpartum haemorrhage\(^{19}\) for first and second line drug regimens and considerations including:  
  o Ergometrine maleate 250 micrograms IV or IM  
  o Misoprostol 800–1000 micrograms per rectum  
  o Critical bleeding massive transfusion protocol |
| Surgical intervention     | • Unstable haemodynamics is a clinical indication for:  
  o Surgical evacuation of the uterus for incomplete EPL  
    ▪ Suction curettage is preferable to sharp curettage as the latter is associated with increased morbidity\(^{20}\)  
  o Laparoscopy and/or laparotomy for removal of ectopic pregnancy  
  o In the second trimester, consider hysterotomy or laparotomy as is indicated |
4  Ectopic pregnancy

Table 8. Ectopic pregnancy

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Context** | - Occurs in 1.5–2% of pregnancies\(^{21}\)  
- Commonly (95%) occur in the fallopian tube\(^{22,23}\)  
- Absence of IUP on USS with a positive serum β-hCG level raises suspicion of an ectopic pregnancy  
- Failure to promptly diagnose and manage an ectopic pregnancy can be life threatening\(^{23}\)  
  - In Australia 2008–2012, five of the 105 maternal deaths were due to ectopic pregnancy\(^{24}\) |
| **Clinical presentation\(^{23}\)** | - Absence of menses  
- Irregular vaginal bleeding (spotting)—but not in all cases  
- Abdominal pain, tenderness and palpable adnexal mass in 50% of women  
- Cervical motion tenderness  
- Absence of IUP on TVS with positive serum β-hCG  
- Suspect a ruptured ectopic if:  
  - Shoulder tip or diaphragmatic pain (10–20% of ruptured ectopics)  
  - Tachycardia/hypotension from profound intraperitoneal haemorrhage |
| **Options for treatment** | - There is limited high level evidence comparing expectant, medical and surgical options with regard to primary treatment success, recurrent ectopic, tubal patency and future IUP rates\(^{25-27}\)  
- Choice of surgical, medical and expectant care\(^{26}\) depends on the clinical situation and woman’s preference\(^{23}\)  
- Offer information to women about the risks and benefits of options for treatment relevant to the clinical circumstances  
- Falling or stationary β-hCG does not exclude the risk of rupture following medical or expectant management |
| **Non fallopian tube ectopic** | - For interstitial (corneal), caesarean scar, cervical, heterotopic, ovarian and abdominal ectopic pregnancies\(^{22}\), surgical or medical management may be appropriate depending on individual circumstances  
  - Methotrexate may be given IV or IM or by injection directly into the sac  
- Individualise management and seek expert advice as required |

4.1  Risk factors for ectopic pregnancy

One third of women diagnosed with an ectopic pregnancy will have no risk factors\(^2\)

Table 9. Risk factors associated with ectopic pregnancy

<table>
<thead>
<tr>
<th>Risk factor(^{22})</th>
<th>(Adjusted*) OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous tubal surgery</td>
<td>4.0*</td>
<td>2.6 to 6.1</td>
</tr>
<tr>
<td>Previous ectopic pregnancy</td>
<td>8.3</td>
<td>6.0 to 11.5</td>
</tr>
<tr>
<td>Infertility (risk increases with length of)</td>
<td>2.1–2.7*</td>
<td>–</td>
</tr>
<tr>
<td>Previous genital infection confirmed</td>
<td>3.4*</td>
<td>2.4 to 5.0</td>
</tr>
<tr>
<td>Previous miscarriage</td>
<td>3.0*</td>
<td>&gt; 2</td>
</tr>
<tr>
<td>Current smoker (risk increases with amount/day)</td>
<td>1.7–3.9*</td>
<td>–</td>
</tr>
<tr>
<td>Smoking (past or ever)</td>
<td>1.5*</td>
<td>1.1 to 2.2</td>
</tr>
<tr>
<td>Intrauterine device use more than 2 years</td>
<td>2.9*</td>
<td>1.4 to 2.3</td>
</tr>
<tr>
<td>Age 40 or older (compared to 25–29 years)</td>
<td>2.9*</td>
<td>1.4 to 6.1</td>
</tr>
<tr>
<td>Sterilisation(^1)</td>
<td>9.3</td>
<td>4.9 to 18.0</td>
</tr>
<tr>
<td>Documented tubal pathology</td>
<td>3.7*</td>
<td>1.2 to 4.8</td>
</tr>
</tbody>
</table>

*adjusted for: previous pelvic infection, smoking, recruitment area, level of education and age  
\(^{1}\) compared with pregnant controls only
### 4.2 Expectant management of ectopic pregnancy

Expectant management is an option for selected women. Clear criteria for selection have not been well defined.\(^\text{26}\)

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Context** | • Among selected cases (early gestation, with β-hCG values below 1000 IU/L and decreasing) up to 70% reported to resolve spontaneously without therapy\(^\text{21}\)  
• Inform women of the possibility of tubal rupture despite decreasing β-hCG |
| **Indicated only if:** | • Haemodynamically stable  
• Low and falling β-hCG (less than 1500 IU/L at initial presentation)\(^\text{28}\)  
• Tubal mass less than 3 cm  
• No pain  
• Nil to minimal evidence of blood in the pelvis on USS  
• No geographical isolation |
| **Cautions** | • Consider individual circumstances  
• Not suitable for women who are potentially non-compliant or not motivated to long term recovery |
| **Ongoing management** | • Follow up via EPAS  
• β-hCG:  
  o Every 48 hours for 8 days (to confirm levels falling)  
  o If satisfactory resolution occurring, may commence weekly levels until negative  
• USS not routinely recommended—consider if:  
  o β-hCG not consistently falling  
  o Clinically indicated  
• Offer surgical or medical management:  
  o At the woman’s request  
  o If there is ongoing or increasing pain or bleeding  
  o β-hCG is not consistently falling  
  o Tubal rupture with haemoperitoneum occurs |
| **Advice for women** | • Refer to Section 1.2 for information/advice requirements  
• Advise:  
  o Pelvic examination and sexual intercourse carry risk of rupture in acute phase of resolution  
  o Avoid future pregnancy until sonographic resolution of mass, noting that sonographic resolution of mass takes longer than biochemical resolution of β-hCG  
• Early USS in next pregnancy (5–6 weeks gestation) |
4.3 Medical management of ectopic pregnancy

Methotrexate is the drug of choice although regimens vary.\textsuperscript{29,30} If no local protocols exist, refer to Appendix C: Methotrexate regimens for ectopic pregnancy.

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Context</strong></td>
<td>• Methotrexate is a folic acid antagonist which prevents the growth of rapidly dividing cells by interfering with DNA synthesis\textsuperscript{31}</td>
</tr>
</tbody>
</table>
| **Indications** | • Unruptured ectopic pregnancy; haemodynamically stable and no signs of active bleeding\textsuperscript{29,29,32}  
• Unusual sites (e.g. cervical ectopic, interstitial, caesarean scar)  
• Low initial serum $\beta$-hCG\textsuperscript{26}  
  o Best results achieved if $\beta$-hCG less than 5000 IU/L\textsuperscript{22} but may be used at any $\beta$-hCG level in the unruptured ectopic\textsuperscript{30}  
• FBC, electrolytes and liver function tests (ELFT) are within normal range |
| **Contraindication\textsuperscript{29}** | • Haemodynamically unstable  
• Allergy to methotrexate  
• Evidence of significant haemoperitoneum on TVS  
• Renal disease/insufficiency (methotrexate cleared via the renal system)  
• Abnormal FBC, ELFT  
• Acute liver disease, aplastic anaemia, thrombocytopenia  
• Immunodeficiency  
• Active pulmonary disease  
• Active peptic ulcer disease  
• Coexistent viable IUP (heterotopic pregnancy)  
• Breastfeeding  
• Potential for non-compliance with prolonged follow-up (35–109 days)  
• Geographic isolation |
| **Cautions\textsuperscript{29}** | • Baseline serum $\beta$-hCG greater than 5000 IU/L  
• Ectopic pregnancy greater than 3–4 cm diameter on TVS  
• Presence of fetal heart motion on TVS  
• When blood transfusion is not acceptable to the woman  
• If body mass index (BMI) greater than or equal to 40 kg/m\textsuperscript{2}, and IMI dosage is capped at 2 m\textsuperscript{2} BSA, an additional dose is more likely to be required to achieve complete resolution\textsuperscript{33} |
| **Ongoing management** | • Follow up with EPAS  
• $\beta$-hCG as per methotrexate protocol  
• Repeat USS in one week and thereafter as clinically indicated (e.g. $\beta$-hCG not consistently falling, ectopic site other than fallopian tube)  
  o If fetal heart present on USS, refer urgently to MFM for follow-up—direct injection of potassium chloride may be indicated |
| **Advice for women** | • Refer to Section 1.2 for information/advice requirements  
• Provide information about usual cytotoxic precautions post treatment with methotrexate  
• Avoid:  
  o Sun exposure (to limit skin inflammation)  
  o Foods and vitamins containing folic acid  
• Advise:  
  o Pelvic examination and sexual intercourse carry risk of rupture in acute phase of resolution  
  o Common side effects of methotrexate include: nausea, tiredness, altered bowel habits and mouth ulcers which usually settle without treatment within a few days  
• Advise to delay next pregnancy for four months post administration of methotrexate due to potential teratogenicity of methotrexate\textsuperscript{34,35}  
  o Ensure sonographic resolution of mass prior to future pregnancy, noting that sonographic resolution of mass takes longer than biochemical resolution of $\beta$-hCG\textsuperscript{36}  
• Early USS in next pregnancy (5–6 weeks gestation) |
4.4 Surgical management of ectopic pregnancy

Table 12. Surgical management of ectopic pregnancy

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
<td>• Woman’s preference</td>
</tr>
<tr>
<td></td>
<td>• Haemodynamic instability</td>
</tr>
<tr>
<td></td>
<td>• Persistent excessive bleeding</td>
</tr>
<tr>
<td>Approach</td>
<td>• Laparoscopy is the method of choice for stable women(^{22})</td>
</tr>
<tr>
<td></td>
<td>• Laparotomy may be required in cases of haemorrhagic shock</td>
</tr>
<tr>
<td>Follow-up</td>
<td>• GP follow-up around 2 weeks post-surgery</td>
</tr>
<tr>
<td></td>
<td>• USS not routinely required—consider if:</td>
</tr>
<tr>
<td></td>
<td>o β-hCG does not fall</td>
</tr>
<tr>
<td></td>
<td>o Other clinical indications</td>
</tr>
<tr>
<td></td>
<td>• If salpingo(s)tomy, weekly β-hCG until negative(^{22})</td>
</tr>
<tr>
<td></td>
<td>o If β-hCG does not fall, consider medical treatment or salpingectomy</td>
</tr>
<tr>
<td></td>
<td>• If salpingectomy</td>
</tr>
<tr>
<td></td>
<td>o Unusually may see abdominal implantation especially after ruptured ectopic with haemoperitoneum</td>
</tr>
<tr>
<td></td>
<td>o Rarely may see ongoing intrauterine gestation if undiagnosed heterotopic pregnancy</td>
</tr>
<tr>
<td></td>
<td>o Urinary β-hCG 3 weeks after surgery</td>
</tr>
<tr>
<td></td>
<td>• Advise early USS in next pregnancy (5–6 weeks gestation)</td>
</tr>
<tr>
<td>Advice for</td>
<td>• Refer to Section 1.2 for information/advice requirements</td>
</tr>
<tr>
<td>women</td>
<td>• There is no data on the optimal conception interval—clinical practice varies from next menstrual period to 3 months</td>
</tr>
<tr>
<td></td>
<td>• Risk of recurrent ectopic pregnancy is approximately(^{37}):</td>
</tr>
<tr>
<td></td>
<td>o 15% after one ectopic pregnancy</td>
</tr>
<tr>
<td></td>
<td>o 30% after two ectopic pregnancies</td>
</tr>
<tr>
<td></td>
<td>• Subsequent IUP rate is 38–89%(^{22})</td>
</tr>
</tbody>
</table>

5 Non-viable intrauterine pregnancy

There are no significant differences between expectant, medical and surgical management for rates of infection,\(^{7,38}\) psychological outcomes,\(^{7,38}\) resumption of normal activities, or subsequent fertility.\(^{39}\)

5.1 Risk factors

Table 13. Risk factors associated with first trimester pregnancy loss

<table>
<thead>
<tr>
<th>Risk factor group</th>
<th>Risk factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal/placental</td>
<td>• Chromosomal abnormalities(^{40})</td>
</tr>
<tr>
<td></td>
<td>• Congenital abnormalities(^{41})</td>
</tr>
<tr>
<td></td>
<td>• GTD</td>
</tr>
<tr>
<td>Maternal</td>
<td>• Maternal age: EPL 7% in 25–29 years versus 43% in 40–44 years(^{3,36})</td>
</tr>
<tr>
<td></td>
<td>• Recurrent miscarriage history: risk of EPL 20–70% after three losses(^{42})</td>
</tr>
<tr>
<td></td>
<td>• Anatomic factors (e.g. uterine septum)</td>
</tr>
<tr>
<td></td>
<td>• Endocrinopathy (e.g. thyroid disease)</td>
</tr>
<tr>
<td></td>
<td>• Immunologic factors (e.g. systemic lupus erythematosus)</td>
</tr>
<tr>
<td></td>
<td>• Infection (e.g. cytomegalovirus)</td>
</tr>
<tr>
<td></td>
<td>• Severe acute illness</td>
</tr>
<tr>
<td></td>
<td>• Thrombophilia (e.g. factor V Leiden)</td>
</tr>
<tr>
<td></td>
<td>• Uncontrolled chronic illness (e.g. diabetes, hypertension)(^{41})</td>
</tr>
<tr>
<td></td>
<td>• Very high or low pre-pregnancy BMI(^{40})</td>
</tr>
<tr>
<td>Other</td>
<td>• Drug use/smoking</td>
</tr>
<tr>
<td></td>
<td>• Teratogen exposure</td>
</tr>
<tr>
<td></td>
<td>• Trauma (e.g. physical abuse)(^{41})</td>
</tr>
</tbody>
</table>
### 5.2 Expectant management of non-viable intrauterine pregnancy

Table 14. Expectant management for stable non-viable IUP

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Indications**             | • Woman’s preference  
• Most suited to the management of incomplete miscarriage<sup>43</sup>                                                                                                                                 |
| **Contraindications**       | • Suspected GTD  
• Haemodynamically unstable  
• Intrauterine device (requires removal)  
• Women at increased risk of haemorrhage (e.g. late in first trimester)<sup>2</sup> or effects of (e.g. unable to have blood transfusion or coagulopathies)<sup>2</sup>  
• Evidence of infection<sup>2</sup>                                                                                                               |
| **Risk/benefit**            | • More days of bleeding and a greater amount of bleeding when compared to surgical treatment<sup>38</sup>  
• The proportion of women who subsequently require surgery varies widely between 2% and 44%<sup>38</sup> which may be explained by management bias  
• Timeframe to complete miscarriage is unpredictable  
• In setting of missed miscarriage, complete resolution may take several weeks and overall efficacy rates are lower<sup>43</sup> |
| **Ongoing management**     | • Arrange follow-up within 7–10 days at GP or EPAS  
• Initial evaluation by history and examination  
  o Remain vigilant for GTD and/or ectopic  
• Repeat β-hCG day 8  
• Consider USS:  
  o If clinically indicated (symptomatic)  
  o To assess for retained POC  
  o If β-hCG level has not fallen more than 90% over 7 days<sup>44</sup>  
• Discuss options for continued expectant management or surgical or medical management:  
  o At the woman’s request  
  o If there is ongoing heavy bleeding, pain or persistent intrauterine gestational sac identified on USS  
  o If other clinical concerns identified (e.g. heavy bleeding, pain)  
• If infection suspected, recommend early surgical management with antibiotic cover  
• Recommend urinary pregnancy test at 3–6 weeks if<sup>9</sup>:  
  o No POC histopathology  
  o Failure to return to normal menstruation by 4–6 weeks  
  o Ongoing abnormal bleeding                                                                                                                             |
| **Advice for women**        | • Refer to Section 1.2 for information/advice requirements  
• Access to a telephone and 24 hour emergency hospital admission is required or a plan for access where there is geographical/social isolation<sup>2,7</sup>  
• Expect bleeding for up to two weeks (or longer in individual cases)  
• Advise surgical or medical management can be chosen at a later date                                                                                      |
## 5.3 Medical management of non-viable intrauterine pregnancy

### Table 15. Indications for medical management for the stable non-viable IUP

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Indications     | • Woman’s preference  
• Missed or incomplete miscarriage to reduce need for surgery                                                                                                                                             |
| Contraindications | • Suspected GTD\(^\text{45}\)  
• Haemodynamically unstable  
• Increased risk of haemorrhage (e.g. late first trimester) or effects of haemorrhage (e.g. coagulopathy, unable to have blood transfusion)  
• Evidence of infection  
• Intrauterine device (requires removal)\(^\text{45}\)  
• Medical contraindications (e.g. hypertension, allergy to prostaglandins\(^\text{45}\))                                                                 |
| Risk/benefit    | • An effective alternative to surgical evacuation for first trimester EPL\(^\text{46}\)  
• More effective for missed miscarriage than expectant management\(^\text{43}\)  
• If incomplete miscarriage, no significant difference between medical and expectant management for rates of\(^\text{8}\):  
  o Complete miscarriage  
  o Need for surgical evacuation  
• Bleeding is heavier and more prolonged after medical treatment with misoprostol than with curettage\(^\text{8,47}\) |
| Misoprostol*    | • Misoprostol is the drug of choice\(^\text{8}\)  
  o Reported 80–99% effective in achieving complete miscarriage\(^\text{8}\)  
• For incomplete miscarriage before 13 weeks, there is little evidence for one specific misoprostol regimen or route of administration over another\(^\text{8,48}\)  
• If no local protocol, recommended regimen is:  
  o Day 1: misoprostol 400–800 micrograms PV, oral or sublingual  
  o Day 2 or Day 3: repeat misoprostol 400–800 micrograms PV, oral or sublingual  
  ▪ If good history of POC passed, second dose may be omitted |
| Administration  | • Treatment may be offered as an outpatient or day procedure\(^\text{46}\)  
• Provide oral analgesia and anti-emetics as required\(^\text{2,46}\)                                                                                                                                            |
| Ongoing management | • Follow up with EPAS on day 2 and day 8  
• Initial evaluation of success is by history and examination  
  o Remain vigilant for GTD and/or ectopic\(^\text{3}\)  
• β-hCG day 1 (day of first misoprostol), and day 8 (to confirm levels falling)  
• Consider USS:  
  o If clinically indicated (symptomatic)  
  o To assess for retained POC  
  o If β-hCG level has not fallen more than 90% over 7 days\(^\text{44}\)  
• Surgical management not indicated within one week of medical management unless\(^\text{55}\):  
  o The woman requests it  
  o There are other clinical concerns (e.g. ongoing heavy bleeding, pain)  
• Recommend urinary pregnancy test at 3–6 weeks if\(^\text{9,50}\):  
  o No POC histology  
  o Failure to return to normal menstruation by 4–6 weeks  
  o Ongoing abnormal bleeding |
| Advice for women | • Refer to Section 1.2 for information/advice requirements  
• Inform women:  
  o Bleeding heavier than menses\(^\text{50}\) is likely  
  o Cramping may accompany bleeding\(^\text{50}\)  
  o If bleeding has not commenced by 24 hours following treatment, to contact her healthcare provider to determine ongoing care\(^\text{2}\)  
  o Potential side-effects include pain, diarrhoea and vomiting\(^\text{2}\) |

\(^\text{*Refer to an Australian pharmacopeia for complete drug information}\)
## 5.4 Surgical management of non-viable intrauterine pregnancy

Table 16. Surgical management of the stable non-viable IUP

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Indications**     | • Woman’s preference  
                      • Unsuccessful medical or expectant management  
                      • Absolute clinical indications for surgical management include:\n                        o Haemodynamic instability  
                        o Persistent excessive vaginal bleeding  
                        o Evidence of infected retained tissue  
                        o Suspected GTD  
                      • Suction curettage is the recommended method<sup>20</sup>                                                                                       |
| **Cautions**        | • No strict contraindications  
                      • Caution if:\n                        o Increased risk of haemorrhage (e.g. suspected arteriovenous malformation or coagulopathy)  
                        o Previous uterine perforation                                                                                                                    |
| **Risk/benefit**    | • As a primary approach, surgical management results in a more immediate outcome with less follow-up<sup>50</sup>  
                      • Standard risks associated with procedure and anaesthesia                                                                                      |
| **Cervical priming**| • Clinical experience supports the use of cervical ripening agents prior to surgical evacuation, although evidence is limited<sup>51</sup>  
                      • If no local protocol, recommended dose is<sup>52</sup>:\n                        o Misoprostol 400 micrograms PV 3–4 hours prior to surgery OR  
                        o Misoprostol 400 micrograms oral, sublingual, buccal 2–3 hours prior to surgery  
                        o Use water as lubricant                                                                                                                          |
| **Care provision**  | • Suction curettage is usually performed under general anaesthetic  
                      • Provide appropriate analgesia<sup>20</sup>  
                      • There is insufficient evidence to support routine antibiotic prophylaxis prior to surgery<sup>53</sup>  
                        - Consider based on individual clinical indications (e.g. endometritis)  
                      • If clinically indicated, consider USS at time of suction curettage                                                                                 |
| **Follow-up**       | • Refer to Section 1.2 for information/advice requirements  
                      • Advise GP follow-up if ongoing clinical concerns  
                      • β-hCG not routinely indicated  
                      • USS not routinely recommended                                                                                                                       |
| **Repeat curettage**| • If repeat curettage is required (experienced operator required):\n                        o Consider initial hysteroscopy to facilitate uterine evacuation and minimise risk of Asherman’s syndrome  
                        o Administer antibiotics                                                                                                                             |

*Refer to the Australian pharmacopeia for complete drug information.*
6 Second trimester pregnancy loss

Second trimester pregnancy loss represents one to two percent of recognised pregnancies.\textsuperscript{54} A cause and effect relationship is difficult to establish and there may be multiple contributing pathologies.\textsuperscript{41,55} There is limited evidence on the best management.\textsuperscript{8}

Table 17. Second trimester loss

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Potential aetiologies</strong></td>
<td></td>
</tr>
<tr>
<td>Fetal</td>
<td>Chromosomal abnormalities\textsuperscript{41}</td>
</tr>
<tr>
<td></td>
<td>Congenital abnormalities\textsuperscript{41}</td>
</tr>
<tr>
<td>Maternal</td>
<td>Previous second trimester loss\textsuperscript{56}</td>
</tr>
<tr>
<td></td>
<td>Uterine malformations \textsuperscript{41,56,57}</td>
</tr>
<tr>
<td></td>
<td>Maternal medical illness (e.g. cardiac disease, autoimmune disease, thrombophilia)</td>
</tr>
<tr>
<td></td>
<td>Preterm rupture of membranes</td>
</tr>
<tr>
<td></td>
<td>Placental complications (e.g. abruption)</td>
</tr>
<tr>
<td></td>
<td>Cervical insufficiency\textsuperscript{41,56}</td>
</tr>
<tr>
<td></td>
<td>Infection—estimated to be implicated in 10% to 25% of cases\textsuperscript{41}</td>
</tr>
<tr>
<td><strong>Presentation</strong></td>
<td>Majority present as intrauterine fetal death (IUFD)\textsuperscript{55}</td>
</tr>
<tr>
<td></td>
<td>May present with preterm labour or premature rupture of membranes</td>
</tr>
<tr>
<td><strong>Assessment</strong></td>
<td>Refer to Section 2 Assessment</td>
</tr>
<tr>
<td></td>
<td>Perform low-vaginal and peri-anal swabs</td>
</tr>
<tr>
<td></td>
<td>Refer to Queensland Clinical Guidelines: Stillbirth care\textsuperscript{58} protocol for maternal investigations</td>
</tr>
<tr>
<td><strong>Care setting</strong></td>
<td>Where feasible, provide care in a setting away from women with uncomplicated pregnancies or healthy babies\textsuperscript{57}</td>
</tr>
<tr>
<td></td>
<td>Provide adequate and appropriate analgesia consistent with the women’s wishes\textsuperscript{57}</td>
</tr>
</tbody>
</table>
### 6.1 Management of second trimester loss

Thoroughly discuss options with the woman and her support person/s, in the context of her unique circumstances. Where there is evidence of maternal compromise (e.g. sepsis, large placental abruption, severe or rapidly worsening pre-eclampsia), expedite birth.

Table 18. Management options

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Management options** | • Both medical and surgical management options may be appropriate, depending on gestation and individual clinical circumstances  
  • When safe to do so, the woman may go home before returning to hospital at a mutually agreed time (or prior if clinically indicated) |
| **Medical management*** | • Appropriate for all gestations  
  • If previous uterine surgery, risk of rupture with misoprostol reported as less than 0.28% [95% CI 0.08 to 1.0]59  
  • If cervix is closed and membranes are intact, mifepristone and misoprostol are first-line agents for induction of labour57  
  o Misoprostol alone may also be used  
  o If no local protocol, refer to Queensland Clinical Guideline: Therapeutic termination of pregnancy60  
  • If membranes are ruptured and/or the cervix is dilated, consider misoprostol or intravenous oxytocin if required57 |
| **Third stage**       | • Active management is recommended  
  • If not complete within 30 minutes:  
    o Notify medical officer  
    o Empty bladder  
    o Consider oxytocin infusion  
  • If not complete within one hour, consider manual removal of placenta  
  • Anticipate and prepare for PPH57  
  • Retain cord, membranes and placenta for histopathology57 |
| **Surgical management** | • May be necessary in cases of persistent excessive bleeding, haemodynamic instability, evidence of retained POC, suspected GTD57  
  • Generally suitable for gestations up to 15 completed weeks  
  o Between 12 and 15 weeks, experienced practitioner required61  
  • May be suitable beyond 16 weeks where baby has died at an earlier gestation and surgery is deemed to be safe |
| **Lactation suppression** | • Milk production can occur as early as 16 weeks  
  o Early milk production is more likely in multigravida women who have breastfed previously62  
  • Where lactation suppression is indicated, recommend conservative and comfort measures (e.g. minimal breast stimulation, cold compresses and analgesia)62  
  • Pharmacological agents  
    o There is weak evidence that pharmacologic treatments are better than no treatment for suppressing lactation63  
    o Exercise caution when considering use of lactation inhibiting medication and consult with relevant health professionals (e.g. pharmacists, lactation consultants) |
| **Follow-up**         | • Arrange follow-up appointment with obstetrician57  
  • Consider postnatal USS to assess for uterine malformations where indicated  
  • Inform GP and provide a clinical summary  
  • Refer to the Queensland Clinical Guideline: Stillbirth care68 for follow-up maternal and fetal investigations (e.g. autopsy, pathology) |

*Refer to the Australian pharmacopeia for complete drug information
7 RhD immunoglobulin

Collect blood group and antibody screen for all women with early pregnancy complications.\textsuperscript{64}

Table 19. Assessment for RhD immunoglobulin

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Context</strong></td>
<td>• Approximately 21% of women in Queensland are RhD negative blood type\textsuperscript{65} • The majority of fetal bleeds are less than 5 mL of red blood cells (4% are greater than 1 mL whole blood)\textsuperscript{66} • There is limited evidence about the risk of sensitisation with bleeding before 12 weeks, but has been reported as early as 6 weeks gestation\textsuperscript{66}</td>
</tr>
<tr>
<td><strong>Contra-indications</strong>\textsuperscript{67}</td>
<td>• RhD positive women • RhD negative women with preformed anti-D antibodies • Previous sensitivity or allergy to RhD immunoglobulin (RhD-Ig) • Woman declines</td>
</tr>
<tr>
<td><strong>Indications 1–12+6 weeks gestation</strong></td>
<td>• Recommend to women without contraindications following\textsuperscript{64,66}: o Miscarriage o Termination of pregnancy o Ectopic pregnancy o Chorionic villous sampling o Hydatidiform mole</td>
</tr>
<tr>
<td><strong>Indications 13+0 weeks and beyond</strong></td>
<td>• Recommend to women without contraindications following\textsuperscript{66}: o Chorionic villous sampling, amniocentesis, cordocentesis or fetoscopy o Abdominal trauma considered sufficient to cause fetomaternal haemorrhage (FMH) (even if Kleihauer negative, as 0.001 mL fetal blood sensitises an RhD negative mother)  ▪ Refer to Queensland Clinical Guideline: Trauma in pregnancy\textsuperscript{68} o Each occasion of revealed or concealed antepartum haemorrhage o External cephalic version (performed or attempted) o Miscarriage or termination of pregnancy</td>
</tr>
<tr>
<td><strong>Quantifying FMH</strong></td>
<td>• If gestation less than 12+6 weeks, quantification of FMH is not required after a sensitising event\textsuperscript{69} • If gestation 13 weeks or more, quantify the magnitude of the FMH with the Kleihauer test to ensure an adequate dose of RhD-Ig is offered o Each 100 IU of RhD-Ig protects against 1 mL fetal red cells (2 mL whole blood)\textsuperscript{70} • If the Kleihauer test is negative, a further dose of RhD-Ig is not required • If the Kleihauer test indicates FMH is greater than that covered by the RhD-Ig dose administered, give an additional dose(s) within 72 hours sufficient to provide immunoprophylaxis • Flow cytometry (the most accurate quantitative test for FMH) may be performed by the laboratory at their discretion • Interpret with caution in women with persistent fetal haemoglobin (e.g. African women, especially if sickle cell traits)</td>
</tr>
</tbody>
</table>
7.1 Administration of RhD immunoglobulin

Table 20. Administration of RhD immunoglobulin

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Information** | • Inform women that RhD-Ig is a blood product  
| | • Obtain consent for administration as for other blood products |
| **Timing/route** | • Administer RhD-Ig as soon as possible after each sensitising event (always within 72 hours)  
| | • If not offered within 72 hours, a dose offered within 9–10 days may provide protection71  
| | • Deep intramuscular injection (IMI) |
| **Intravenous Rophylac®** | • Not indicated for routine prophylaxis in RhD negative women  
| | • May be indicated for use in large FMH where administration of IM RhD-Ig is either contraindicated or not practical or for inadvertent or emergency transfusion of RhD positive blood to an RhD negative female of childbearing potential72  
| | • Rophylac® 1500 IU administered IV will suppress the immunising potential of up to 15 mL of RhD positive red cells72 |
| **BMI greater than 30 kg/m²** | • Consider the adequacy of injection site and length of needle used73  
| | • No additional routine testing or dosing required73  
| | • If BMI greater than 30 kg/m² and FMH greater than 6 mL, intravenous administration may be considered for any additional doses  
| | o Increases bioavailability and facilitates more rapid clearance of fetal cells |

<table>
<thead>
<tr>
<th><strong>Dose of IMI RhD-Ig</strong></th>
<th>For each sensitising event</th>
<th>Dose (IMI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Singleton pregnancy of 1–12+6 weeks gestation</td>
<td>250 IU</td>
</tr>
<tr>
<td></td>
<td>Multiple pregnancy (any gestation)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gestation uncertain but possibly 13 or more weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gestation 13+0 weeks or beyond</td>
<td>625 IU</td>
</tr>
</tbody>
</table>

*Refer to the Australian pharmacopeia for complete drug information

7.2 Threatened miscarriage

Table 21. Threatened miscarriage

<table>
<thead>
<tr>
<th>Gestation</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **1–12+6 weeks** | • Insufficient evidence to support routine use of RhD-Ig for bleeding in an ongoing pregnancy56  
| | • If there is heavy or repeated bleeding, or bleeding associated with abdominal pain, significant abdominal trauma or a visible subchorionic haematoma, individualise RhD-Ig administration according to clinical circumstances66,69 |
| **13+0 weeks and beyond** | • Quantify FMH at one or two weekly intervals69  
| | • If a new sensitising event is suspected in addition to continued bleeding, (e.g. change in symptoms or pattern or severity of bleeding) manage as an additional sensitising event  
| | • If Kleihauer is positive on any test, give an additional dose of RhD-Ig sufficient to provide immunoprophylaxis69 |
8 Gestational trophoblastic disease

GTD is classified as two premalignant diseases (complete hydatidiform mole (HM) and partial HM) and as four malignant disorders (invasive mole/persistent trophoblast neoplasia, choriocarcinoma, placental site trophoblastic tumour (PSTT) and epithelioid trophoblastic tumour (ETT)). The latter four malignant conditions are often collectively referred to as gestational trophoblastic neoplasia (GTN).74

Table 22. Gestational Trophoblastic Disease

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Considerations</th>
</tr>
</thead>
</table>
| Clinical presentation | • Most common presentation is abnormal vaginal bleeding  
                          • More common in Asia (as high as 2 per 1000 pregnancies) compared with Europe and North America (less than 1 per 1000 pregnancies75) |
| Diagnosis | • Complete HM are more likely than partial HM to be identified by their characteristic USS features  
             • Normal USS does not exclude the diagnosis of a HM76  
             • A quantitative β-hCG is recommended  
             • Definitive diagnosis is made by histological examination of the POC76 |
| Interventions | • Register women with the Queensland Trophoblast Centre (QTC)  
                      • Suction curettage with concomitant administration of IV uterotonic agents (e.g. oxytocin) is required75  
                      • Although there is limited evidence, misoprostol for pre-surgical cervical priming may be considered  
                      • If GTD is demonstrated by histopathology following medical or expectant management:  
                        o Close follow-up indicated  
                        o If ongoing bleeding, β-hCG not clearing, or USS indicates retained POC, then surgery may be indicated |
| Persistent trophoblastic disease | • In a series of 686 women, 4.7% with partial HM and 16.5% of complete HM, developed persistent disease which required treatment77  
                                        • Risk increases progressively with the time taken to reach negative β-hCG after evacuation (more than 100 fold when the interval exceeded 12 weeks77)  
                                        • Consider persistent disease where there is:  
                                          o Increased, stationary or inadequately falling β-hCG trend on three consecutive weeks at any time following surgical evacuation  
                                          o Continued PV bleeding and detectable β-hCG  
                                          o Evidence of metastases in the presence of detectable β-hCG |
| Follow-up | • Aim is to exclude persistent GTD76  
                 • Recommend effective contraception to avoid pregnancy during follow-up  
                 • Perform β-hCG levels 6 weeks after any future pregnancy  
                 • If β-hCG decreases spontaneously in HM, routine chest x-ray not required |
| Partial HM | • Weekly serum β-hCG levels until negative for three consecutive weeks  
                 • Conception may be attempted immediately after three consecutive negative β-hCG results  
                 • Annual follow-up for five years with QTC |
| Complete HM | • Weekly serum β-hCG until negative for three consecutive weeks  
                  • Then monthly for 6 months after the third negative result  
                  • Conception may be attempted immediately after the six months of consecutive negative β-hCG results are finalised  
                  • Annual follow-up for five years with QTC |
| Queensland Trophoblast Centre (QTC) | • Mortality with GTD treated at a trophoblast centre was 2.1% compared to 8% among women referred after failure of primary treatment79  
                                        • Register all women with the QTC at the Royal Brisbane and Women’s Hospital, Queensland 4029  
                                        • Contact QTC:  
                                          o For any clinical concerns  
                                          o In all cases of persistent GTD  
9 Psychological support

Early pregnancy loss is an experience common to many women, and yet it is simultaneously an intensely personal, private, intimate and individual experience.\textsuperscript{80} It is important for longer term health and wellbeing, that a woman’s psychological needs are not overlooked, and that any symptoms of grief, depression and anxiety are recognised and acknowledged by health professionals.\textsuperscript{81}

9.1 Context and experience of early pregnancy loss

Table 23. Context and experience of early pregnancy loss

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Context | • Approximately one third of women experience at least one EPL\textsuperscript{4}  
• Historically, maternal grief following a EPL was presumed to be mild and short lived, but has been more recently recognised as significant as losing any loved one\textsuperscript{81} |
| Unique challenges of EPL | • Often sudden and unexpected, limiting the opportunity for anticipatory grieving and practical preparation\textsuperscript{81}  
• Encompasses both the loss of a baby, and the loss of future dreams and possibilities\textsuperscript{80,82,83}  
• The loss is largely invisible and hidden (as distinct from loss later in pregnancy)  
• May be largely unacknowledged by family, friends and society in general contributing to a feeling of isolation and secrecy\textsuperscript{81,84}  
• Frequently no formal or public commemoration, funeral or ritual to mark the loss  
• Often a sense of taboo, stigma and silence which can make it difficult to move through the grieving process\textsuperscript{81,82,85}  
• Society can trivialise the impact and downplay the need for women to mourn their loss\textsuperscript{8}  
• Can be perceived as a failure of her own body\textsuperscript{80}  
• Often no known cause, contributing to a sense of confusion, failure, and self-blame  
  o Ascribing an explanation for the loss can bring some resolution and reduce feelings of personal responsibility and guilt\textsuperscript{80,86,87}  
• The meaning women attach to their pregnancies varies, and in turn affects the way they interpret an EPL. Feelings range from relief through to devastation\textsuperscript{4}  
• Partners may experience and respond differently to the loss |
| Care setting | • Minimise waiting times, particularly in public areas such as waiting rooms  
• Consider each woman’s unique situation and context (e.g. previous history of EPL, multiple pregnancy, geographical challenges)  
• Where feasible, offer inpatient care away from maternity units where other mothers and babies are located  
• Offer and facilitate the presence of a support person for all care provision as appropriate  
• Non-directive pregnancy support counselling services are provided under Medicare to a person who is currently pregnant or has been pregnant in the preceding 12 months\textsuperscript{88} |
9.2 Communicating with parents

Table 24. Psychological support considerations

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **General principles** | • Ensure both parents are present at discussions if feasible, and offer inclusion of a support person where appropriate  
  • Ensure both written and verbal information given is consistent  
  • Avoid speculation regarding the cause and explain that the cause of EPL often remains unexplained  
  • Express sorrow for what has happened  
    o Offering sympathy is not an admission of guilt or error  
  • Be open and honest in dealings with parents  
  • Allow time for parents to ask questions, consider treatment options and make decisions  
  • Repeat important information as stress and grief may interfere with comprehension and recall of information |
| **Sharing information** | • Information is critical in increasing knowledge and understanding, and in facilitating control and coping whilst also decreasing distress, fear and anxiety  
  o 93% of women reported that seeking of information was a helpful strategy for coping with their loss  
  • Information about the prevalence of EPL may help women come to terms with loss and reduce feelings of guilt, shame and personal failure  
  • Offer practical information (including written resources) on issues including:  
    o What their baby remains may look like (where appropriate)  
    o The grieving process  
    o Options for the disposal of baby remains [refer to Section 11] |
| **Communication tips** | • Do:  
  o Use the word “baby” (as opposed to “fetus” or “POC”)  
  o Say “I am sorry for your loss”  
  o Call baby by given name (if named) when making/creating memories  
  o Refer to parents as mum and dad to the baby  
  • Do not say:  
    o You can always have another baby  
    o You’re lucky to have other children  
    o It was for the best or everything happens for a reason  
  • Do not try to “cheer them up”  
  • Inform parents that well-meaning family and friends may say hurtful things |
| **Breaking bad news** | • Take great care in being sensitive when delivering bad news. Moments such as these frequently remain engraved in women’s memories, and they are often able to reconstruct the scene and words used in detail  
  • The most experienced practitioners are required for these difficult conversations  
  • Train sonographers and other health professionals in breaking bad news sensitively  
  • Inform parents of diagnosis in a timely manner  
  • Provide a private environment and ensure confidentiality  
  • Provide opportunity for parents to see absence of heartbeat on screen in USS where appropriate  
  • Offer USS results in writing and/or a photo as a memento  
  • Communicate empathetically, clearly and honestly  
  • Use empathetic but unambiguous language (e.g. ‘your baby has died’)  
  • When appropriate, reassure the woman that the loss was not due to anything she did or did not do  
  • Listen reflectively to the parents and give comprehensive answers to questions  
  • Provide support after hearing bad news such as quiet time and opportunity to contact close family/friends |
9.3 Supportive care

Table 25. Supportive care

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **General principles** | • Emotional care is central to women’s perception about the quality of care received  
• Treat women with early pregnancy complications with dignity and respect, being aware that women will react in different ways  
• Empathy, compassion, warmth, kindness, patience, gentleness and understanding are essential characteristics for health care providers  
• Take the time to listen and be present and support the woman to mourn and experience the event in her own way  
• Recognise the loss and acknowledge the importance of this baby no matter how early the loss occurs  
• Inform parents that they can make their own decisions as to what happens to their baby                                                                 |
| **Grief and mourning** | • Allow time for the woman to respond to her loss and offer her a space to discuss her feelings  
• Express genuine concern and demonstrate emotional awareness  
• Counsel women regarding the potential to experience symptoms of grief, depression and anxiety following an EPL  
• Provide information about accessing additional psychological support in the future |

9.4 Creating memories

Table 26. Memory creation

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **Individual preferences** | • Parents may or may not wish to create memories of their pregnancy/baby  
• Discuss options for memory creation with the parents as appropriate to the gestational age, circumstances and cultural preferences  
• Obtain parental consent prior to creating/gathering mementos (as may not always be culturally appropriate)  
• Where immediate memento creation is declined, offer to provide mementos to parents (or family) in a sealed envelope for future access  
  o Storing mementos with hospital records is not recommended as they may be lost or misplaced especially as electronic medical records become more common and replace hard copy records |
| **Seeing the baby** | • Where desired, give parents the opportunity to see and/or hold their baby  
  o Some women wish to avoid this, whereas others may place importance on seeing their baby  
  o Prepare the woman/family for what they may see  
• Following second trimester loss, it may be possible to collect memories such as photographs, handprints and footprints, or to bath the baby  
  o Complete all swabs and tests on baby before bathing  
• Offer options to include extended family (e.g. photographs of family groups, relatives/siblings) |
| **Mementos**    | • Suggestions to support memory creation include:  
  o Apply for an EPL recognition certificate from the Department of Births, Deaths, Marriages and Divorces  
  o Create a keepsake box to keep sentimental items in  
  o Collect mementos such as USS photos, initial positive pregnancy test, hospital identification tags, cot card, sympathy cards, toys or clothes that had been purchased for the baby  
  o Name the baby  
  o Choose a keepsake (e.g. jewellery, ornament, or special quilt)  
  o Create a memorial (e.g. special plant or seat in garden)  
  o Keep a journal of events, thoughts and feelings, or notes or poems to or about baby |

Refer to online version, destroy printed copies after use
9.5 Psychological morbidity

Table 27. Psychological morbidity

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| After EPL                     | • Suicide is the leading cause of maternal death in Queensland and Australia\(^{24,95}\)  
  ○ One of eight maternal suicides in Queensland in 2012–2013 occurred following an EPL\(^{95}\)  
  • A Finnish study reported significantly higher suicide rate following EPL (18.1 per 100 000) than after birth (5.9 per 100 000) or in the general population (11.3 per 100 000)\(^{96}\)  
  • 50% suffer some form of psychological morbidity\(^{81}\)  
  • 40% suffer symptoms of grief immediately\(^{81,90}\), including sadness, longing for the lost baby, a desire to discuss the loss with others and search for a meaningful explanation  
  • Depressive symptoms occur in 12–55% and a similar proportion of women fit the criteria for a major depressive disorder following miscarriage\(^{81,90}\)  
  • Elevated anxiety symptoms reported in 20–40%\(^{81,90}\)  
  • Pathological grief (characterized by despair, deep feelings of worthlessness and hopelessness, and difficulty resuming normal interactions and activities of daily life)\(^{81}\) can develop  
  • Exacerbation of pre-existing mental health issues  
| Risk factors for psychological morbidity | • History of mental illness\(^{85}\)  
  • Stress and negative life events around time of loss\(^{85}\)  
  • Dissatisfaction with primary care provider\(^{85}\)  
  • Lower level of education\(^{85}\)  
  • No living children at the time of pregnancy loss\(^{90}\)  
  • Lack of social support\(^{90}\)  
  • High levels of self-criticism\(^{97}\)  
  • Later gestational age\(^{97}\)  
| Prevention | • Assess for psychological risk factors and refer to mental health services when required\(^{92}\) (e.g. suicidal ideation)  
  • Assess each woman’s response to EPL, and individualised care\(^{89,92}\)  
  • Remember that an EPL, while common within the clinical setting, is a significantly distressing event and that nearly half of women experience psychological morbidity\(^{89,92,90}\)  
  • Be proactive rather than reactive in meeting emotional and physical needs to avoid the woman feeling forgotten, alone or abandoned\(^{89,92}\)  

10 Recurrent early pregnancy loss

While recurrent early pregnancy loss is defined as three or more consecutive miscarriages, consider the individual circumstances of each woman when determining if further investigation is warranted after EPL (e.g. the woman’s age in relation to her opportunity to achieve a live birth).

<table>
<thead>
<tr>
<th>Table 28. Recurrent early pregnancy loss</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Care provision</td>
<td>• Specialist gynaecological consultation is recommended&lt;br&gt;• If underlying medical conditions are suspected, refer to specialist physicians as indicated&lt;br&gt;• Individualise the investigation of recurrent EPL based on a comprehensive history of both partners and the clinical circumstances&lt;br&gt;• Investigation is often disappointing with many unanswered questions regarding aetiology, evaluation and management</td>
</tr>
<tr>
<td>Risk factors</td>
<td>• Epidemiological factors&lt;br&gt;  o Advanced maternal age: risk 51% at 40–44 years; 93% at greater than 45 years&lt;sup&gt;98&lt;/sup&gt;&lt;br&gt;  o Risk of EPL increases after each successive loss (40% after three consecutive losses)&lt;br&gt;• Anatomical factors (e.g. congenital uterine malformations)&lt;br&gt;• Endocrine factors (e.g. diabetes mellitus, thyroid, polycystic ovary syndrome)&lt;br&gt;• Genetic factors&lt;sup&gt;98&lt;/sup&gt;&lt;br&gt;  o Chromosomal abnormalities of the embryo account for 30–57% of further EPL&lt;br&gt;  o Chromosomal anomaly present in one partner in 2–5% of couples&lt;sup&gt;98&lt;/sup&gt;&lt;br&gt;• Antiphospholipid antibodies: present in 15% of women with recurrent EPL&lt;br&gt;• Infective agents&lt;br&gt;• Inherited and acquired thrombophilia</td>
</tr>
<tr>
<td>Standard investigations</td>
<td>• Full Blood Count&lt;br&gt;• ELFT&lt;br&gt;• Thrombophilia screen&lt;br&gt;• Fasting homocysteine and MTHFR (methylene-tetrahydrofolate reductase)&lt;br&gt;• Antiphospholipid antibodies&lt;br&gt;• Thyroid function tests&lt;br&gt;• Fasting insulin&lt;br&gt;• Fasting blood glucose level&lt;br&gt;• POC for fetal karyotyping&lt;br&gt;• Parental chromosomes&lt;br&gt;• Pelvic USS to assess anatomy of the uterus and fallopian tubes&lt;br&gt;• Sperm testing</td>
</tr>
<tr>
<td>Potential treatments</td>
<td>• As indicated by individual clinical circumstances&lt;br&gt;• May include low dose aspirin, enoxaparin, progesterone pessaries, or steroids</td>
</tr>
</tbody>
</table>
11 Sensitive management of fetal tissue/remains

The decisions parents make after EPL can have a significant impact on the grieving process. Even where there is no legal requirement for a funeral, burial or cremation, parents may still desire this option or return months, or even years, later to enquire about the manner in which their baby was disposed of.99

Table 29. Sensitive disposal of fetal remains

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Recommendation</th>
</tr>
</thead>
</table>
| **Birth registration** | • It is compulsory to register the birth of a baby born in Queensland if any of the following conditions are met. Baby is:  
  o Born alive (a baby whose heart has beaten after delivery of the baby is completed100)  
  o 20 weeks or more gestation  
  o 400 g or more  
  • If birth registration is compulsory (i.e. one or more of the above conditions are met), a death certificate and burial or cremation are also compulsory and perinatal data collection is required  
  • If birth registration is not compulsory (i.e. none of the above conditions are met), then a death certificate, burial or cremation, and perinatal data collection are not required  
  • Inform parents that an ‘Early pregnancy loss recognition certificate’ can be obtained free of charge from the Registry of Births, Deaths Marriages and Divorces |
| **Management options** | • Queensland Health facilities may release a deceased fetus which does not require burial or cremation to the parents, provided that:  
  o The facility is satisfied there is no risk of transmission of notifiable conditions  
  o Parents have been informed as to the manner in which the fetal tissue/remains may be lawfully disposed of  
  • Options for disposal include:  
    o Hospital disposal by cremation  
    o Transfer to a funeral director for private arrangements  
    o If there are no prohibiting local council requirements, burial on private property |
| **Facility responsibilities** | • Develop local options and protocols to facilitate sensitive disposal of fetal remains including (but not limited to):  
  o Identification of local council requirements (if any) regarding burial on private property  
  o Release of fetal remains to parents and subsequent return for hospital cremation  
  o Documentation in case of community queries regarding the transport and/or disposal of fetal remains  
  • Document in the health record, the arrangements that are made for fetal tissue disposal |
| **Information provision** | • Inform parents clearly and sensitively of the options available  
  • Allow time for decision making (including when disposal occurs) and provide written information where possible  
  • If parents choose to take fetal remains home, provide information about temperature and timeframes for optimal preservation (e.g. intermittent refrigeration) and expected look and feel  
  • Advise that cremation of fetal tissue does not often produce any ashes to scatter101  
  • Respect the wishes of parents who may not want to be involved |
References


# Appendix A: Early pregnancy assessment service

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benefits of dedicated EPAS</strong></td>
<td>• Streamlining of care and improved efficiency and higher quality of care</td>
</tr>
<tr>
<td></td>
<td>• Reduction in admissions and shorter inpatient hospital stay for those</td>
</tr>
<tr>
<td></td>
<td>requiring admission</td>
</tr>
<tr>
<td></td>
<td>• Greater satisfaction from women regarding their perceived quality of care*</td>
</tr>
<tr>
<td><strong>Service provision</strong></td>
<td>• May be provided by</td>
</tr>
<tr>
<td></td>
<td>o Obstetricians and gynaecologists</td>
</tr>
<tr>
<td></td>
<td>o GP obstetricians</td>
</tr>
<tr>
<td></td>
<td>o GPs in community/rural settings</td>
</tr>
<tr>
<td></td>
<td>o Nurse Practitioners with relevant skill-set</td>
</tr>
<tr>
<td></td>
<td>• Network with a dedicated EPAS for consultation and referral as required</td>
</tr>
<tr>
<td><strong>Service requirements</strong></td>
<td>• An appointment system</td>
</tr>
<tr>
<td></td>
<td>• A discrete waiting area and appropriate consultation room</td>
</tr>
<tr>
<td></td>
<td>• USS equipment (including transvaginal probe) or access to USS evaluation</td>
</tr>
<tr>
<td></td>
<td>• Easy access to laboratory facilities for:</td>
</tr>
<tr>
<td></td>
<td>o RhD antibody testing</td>
</tr>
<tr>
<td></td>
<td>o Selective serum β-hCG</td>
</tr>
<tr>
<td></td>
<td>o Ideally progesterone estimation</td>
</tr>
<tr>
<td></td>
<td>• Be available on a daily basis Monday to Friday</td>
</tr>
<tr>
<td></td>
<td>o If possible available on weekends and after hours</td>
</tr>
<tr>
<td><strong>Governance</strong></td>
<td>• Establish governance and accountability for clinical practice</td>
</tr>
<tr>
<td></td>
<td>• Identify defined lines of communication</td>
</tr>
<tr>
<td></td>
<td>• Determine clinical inclusion/exclusion criteria based on the Clinical</td>
</tr>
<tr>
<td></td>
<td>Service Capability Framework</td>
</tr>
<tr>
<td></td>
<td>• Establish written pathways for clinical management</td>
</tr>
<tr>
<td></td>
<td>• Provide guidance for appointment booking (i.e. referral only or self-</td>
</tr>
<tr>
<td></td>
<td>referral)</td>
</tr>
<tr>
<td></td>
<td>• Establish referral and transfer of care pathways within and external to the</td>
</tr>
<tr>
<td></td>
<td>service</td>
</tr>
<tr>
<td><strong>Documentation</strong></td>
<td>• Access to standardised written patient information</td>
</tr>
<tr>
<td></td>
<td>• Referral and transfer of care (discharge) letters available</td>
</tr>
</tbody>
</table>

## Appendix B: Sonographic anatomy, landmarks and documentation

### Sonographic landmarks:

TVS is recommended for the accurate assessment of early pregnancy.

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Findings</th>
</tr>
</thead>
</table>
| **Gestational sac**         | • Earliest sonographic finding in pregnancy  
• Use Mean sac diameter (MSD) to determine gestational age before crown rump length (CRL) can be clearly measured  
• Usually visible (with TVS) from 4 weeks and 3 days after LNMP  
• True gestational sac is eccentrically placed within the endometrial cavity and surrounded by ‘echogenic ring’ on TVS  
  o Intra-cavity fluid (previously called ‘pseudo gestational sac’) is in the midline of the endometrial cavity, displacing the anterior and posterior surfaces of the endometrial cavity  
• With a positive pregnancy test and no signs of intra or extra uterine pregnancy on TVS, pregnancy is identified as PUL |
| **Yolk sac**                | • Yolk sac is usually first structure visible within the gestational sac and usually visible by 5.5 weeks gestation or MSD of 8–10 mm  
• Presence of yolk sac is definitive evidence to differentiate a sac into a gestational sac  
• Number of yolk sacs usually indicates the number of amniotic sacs in the case of twin pregnancies (i.e. two yolk sacs indicated a diamniotic pregnancy, MCMA twins have one yolk sac) |
| **Embryo and cardiac activity** | • The fetal pole (embryonic disc) is usually visible by 5–6 weeks gestation  
• CRL at 6 weeks and 0 days is 4 mm  
• During the embryonic period (weeks 6–10) the CRL increases about 1 mm per day  
• Cardiac activity is routinely detected by 6 to 6.5 weeks gestation  
• Before 6 weeks gestation, the cardiac rate will be slow (i.e. between 100 and 115 beats per minute, and increases rapidly after 6 weeks) |
| **Corpus luteum**           | • Can vary greatly in appearance, from solid to cystic forms, up to 3cm in size  
• Peripheral vascularity often detected |
| **Early first trimester dating** | • Gestational sac (no yolk sac, embryo or heartbeat) = 5 weeks  
• Gestational sac and yolk sac (no embryo, no heartbeat) = 5.5 weeks  
• Gestational sac and yolk sac (living embryo, CRL less than 5 mm (too small to measure) = 6 weeks  
• When CRL available, use Australasian Society of Ultrasound Medicine measurements to date the pregnancy |


### Standard ultrasound documentation

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Information required</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Approach</strong></td>
<td>Specify if TVS or TAS to aid interpretation</td>
</tr>
</tbody>
</table>
| **Patient history** | LNMP if known and estimated date of delivery by LNMP  
• Any USS performed in the current pregnancy and the results  
• Whether β-hCG (urine or serum) performed and when |
| **Intrauterine:** | Presence of intrauterine sac and if visualised whether single or multiple  
• Mean sac diameter in mm and estimated gestation  
• Presence of yolk sac  
• Presence of fetal pole and the length  
• Presence of fetal heart movement and/or rate in beats per minute (bpm)  
• Presence and size of any peri-gestational bleed  
• Gestational age in weeks and days and estimated date of delivery by this USS  
• Presence and size of retained POC  
• If multiple pregnancy, number of yolk sacs and chorions, and thickness of dividing membrane  
• Possible ectopic intrauterine implantation (cornual, intramural, cervical, scar, ectopic) |
| **Extraterine:** | Ovary—left and right  
• Adnexa—left and right  
• Presence of free fluid and volume (minimal, moderate, extensive) if any |
Appendix C: Methotrexate regimens for ectopic pregnancy

Follow local protocols for the safe administration/disposal of cytotoxic medications and equipment. Refer to the Australian pharmacopeia for complete drug information.

### Intramuscular injection (IMI) methotrexate

| Indications | • Unruptured tubal ectopic pregnancy with all of the following:  
| | o β-hCG less than 3000 IU/L  
| | o Fetal sac less than 3.5 cm  
| | o NO fetal cardiac activity  |
| Dose calculation | • Dose is calculated per square meter of Body Surface Area (BSA)  
| | o BSA = the square root of [Height (cm) x Weight (kg) divided by 3600]  
| | • No consensus on methotrexate dose capping, but commonly capped at 2 m² BSA (equivalent to methotrexate 100 mg IMI)  
| | o If capped, morbidly obese women may require an additional dose  
| | o If BSA greater than 2 m² seek expert advice  |
| Prior to commencement | • FBC, ELFT, β-hCG prior to each dose of methotrexate  
| | • Antiemetic 30 minutes prior to methotrexate (i.e. ondansetron 8 mg IV (or oral) OR granisetron 3 mg IV)  |
| Post-dose | • Monitor woman for 30 minutes post methotrexate administration for hypersensitivity reactions (rare), consider antihistamine or steroid cream  
| | • Give ondansetron 4 mg BD PRN for 2 days  |
| Day 1 (Treatment day) | • β-hCG  
| | • Methotrexate 50 mg/m² BSA IMI (rounded to the nearest 5 mg)  |
| Day 4 | • β-hCG  |
| Day 7 | • β-hCG  
| | • If day 7 β-hCG reduction is less than 15% of day 4 β-hCG, (or if no day 4 level, then less than 25% of day 1 β-hCG) give a second dose of methotrexate 50 mg/m² BSA IMI  |
| Day 14 | • β-hCG  
| | • If day 14 β-hCG reduction is less than 15% of day 7 β-hCG, give a third dose of methotrexate 50 mg/m² BSA IMI  |
| β-hCG | • Monitor the β-hCG weekly until less than 5 IU/L  |

### Intravenous injection (IVI) methotrexate

| Indication | • Any stable ectopic pregnancy at the discretion of the physician, particularly if any of the following:  
| | o β-hCG greater than 3000 IU/L  
| | o Fetal sac greater than 3.5 cm  
| | o Presence of cardiac activity  |
| Prior to commencement | • β-hCG, FBC, ELFT  
| | • Ensure adequate hydration  
| | • 24 hours prior (or as soon as practical) ensure urinary pH greater than 7.0  
| | o Give two sachets of sodium citrotartrate 6 hourly and prn  
| | o Test each urinary void during treatment and prior to discharge  |
| Commence as inpatient | • Antiemetic 30 minutes prior to methotrexate (i.e. ondansetron 8 mg IV (or oral) OR granisetron 3 mg IV)  
| | • Loading dose of methotrexate 100 mg IV stat, over 5–10 minutes  
| | • Then methotrexate 200 mg IV infusion in 500 mL 0.9% sodium chloride over 12 hours  |
| Post loading dose folinic acid (inpatient or outpatient) | • Give ondansetron 4 mg BD PRN for 2 days  
| | • Give folinic acid 15 mg oral (leucovorin) at each of the following times (timing is critical):  
| | o 30 hours post-loading dose of methotrexate  
| | o 42 hours post loading dose of methotrexate  
| | o 54 hours post loading dose of methotrexate  
| | o 66 hours post loading dose of methotrexate  
| | • Confirm timings with follow-up telephone call the day after discharge  |
| β-hCG | • Monitor the β-hCG weekly until less than 5 IU/L  |

NB: In some circumstances, alternative treatment may involve USS guided direct injection of methotrexate into ectopic pregnancy (plus or minus feticide). Seek expert advice.
Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Lead
Dr David Baartz, Senior Staff Specialist, Royal Brisbane and Women’s Hospital

QCG Program Officer
Cara Cox, Clinical Nurse Consultant
Jacinta Lee, Manager

Working Party Members
Ms Julie Algate, Clinical Midwife, Nambour General Hospital
Mrs Stephanie Azri, Team Leader, Logan Central Community Health Centre
Ms Julia Bertolone, Clinical Nurse Coordinator, Mater Mother's Hospital
Dr Elize, Bolton, Clinical Director, Bundaberg Hospital
Ms Julia Brownlie, Nurse Practitioner, Royal Brisbane and Women's Hospital
Mrs Allison Burton, Registered Midwife, Royal Brisbane and Women's Hospital
Mrs Susan Callan, Clinical Midwife Consultant, Royal Brisbane and Women's Hospital
Mrs Katie Cameron, Member, Maternity Consumers Network, Toowoomba
Dr Leanne Chapman, Staff Specialist, Logan Hospital
Mrs Allison Corcoran, Registered Nurse, Royal Brisbane and Women's Hospital
Mrs Paula Dillon, Registered Midwife and Childbirth and Perinatal Loss Educator, Brisbane
Mrs Carole Dodd, Clinical Midwife, Caboolture Hospital
Mr Nigel Duncan, Registered Midwife, Logan Hospital
Dr Wendy Dutton, Director of Obstetrics and Gynaecology, Redland Hospital
Dr Hasthika Ellepola, Staff Specialist, Logan Hospital
Miss Emma Gardner, Clinical Nurse, Royal Brisbane and Women's Hospital
Mr John Graham, Registered Midwife, Caboolture Hospital
Dr Nichole Harvey, Senior Lecturer, James Cook University
Dr Elisabeth Hoehn, Medical Director, QLD Centre for Perinatal and Infant Mental Health, Brisbane
Mrs Aynsley Hunter, Clinical Midwife and Nurse, Ipswich Hospital
Ms Jacqueline Kettewell, Registered, Royal Brisbane and Women's Hospital
Mrs Sharon Kiggins, Clinical Midwife Specialist, Campbelltown, Sydney
Associate Professor Rebecca Kimble, Senior Staff Specialist, Royal Brisbane and Women’s Hospital
Dr Christopher King, Director of Obstetrics and Gynaecology, Mount Isa Hospital
Ms Emma Knowland, Clinical Nurse and Clinical Facilitator, Royal Brisbane and Women's Hospital
Ms Janelle Laws, Nurse Educator, Royal Brisbane and Women's Hospital
Ms Meredith Lovegrove, Clinical Midwife, Rockhampton Base Hospital
Dr Bruce Maybloom, General Practitioner, Victoria Point
Mrs Melanie McKenzie, Consumer representative, Harrison's Little Wings
Dr Heather McNamee, Visiting Medical Officer, Cairns North Community Health Facility
Mrs Nicole Payne, Registered Nurse and Midwife, Royal Brisbane and Women's Hospital
Dr Scott Petersen, Staff Specialist, Brisbane
Dr Jane Reeves, Obstetrician and Gynaecologist, Sunshine Coast
Miss Sally Rouhan, Registered Nurse and Midwife, Kingaroy
Dr Renuka Sekar, Staff Specialist Maternal Fetal Medicine, Royal Brisbane and Women's Hospital
Ms Emma Shipton, Registered Midwife, Royal Brisbane and Women's Hospital
Ms Theona Stone, Nurse Practitioner, Cairns Hospital
Dr Graeme Walker, Gynaecology Director, Gold Coast University Hospital
Dr Fiona Watson, Principal House Officer, Bundaberg Base Hospital
Dr Christopher Weekes, Senior Medical Officer, Caboolture Hospital

Queensland Clinical Guidelines Team
Associate Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Sutherns, Clinical Nurse Consultant
Dr Brent Knack, Program Officer
Ms Cara Cox, Clinical Nurse Consultant
Mr Majid Shams Nosrati, Senior Technical and Administrative Officer
Steering Committee

Funding
This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health